Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by López, J. A.
Right arrow Articles by Berndt, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by López, J. A.
Right arrow Articles by Berndt, M. C.
Related Collections
Right arrow Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Next Article next article arrow

Blood, Vol. 91 No. 12 (June 15), 1998: pp. 4397-4418

REVIEW ARTICLE

Bernard-Soulier Syndrome

By José A. López, Robert K. Andrews, Vahid Afshar-Kharghan, and Michael C. Berndt

From the Departments of Medicine and Molecular and Human Genetics, Baylor College of Medicine and VA Medical Center, Houston, TX; and the Hazel and Pip Appel Vascular Biology Laboratory, Baker Medical Research Institute, Prahran, Australia.

    INTRODUCTION
Introduction
References

IN 1948, BERNARD AND SOULIER described a young male patient with a severe bleeding disorder that was characterized by a prolonged bleeding time, thrombocytopenia, and extremely large platelets.1 They termed the disorder "la dystrophie thrombocytaire-hémorragipare congénitale." Since then, an identical or similar disorder has been described in a large number of individuals, virtually always transmitted in an autosomal recessive manner and often occurring in persons whose parents are close relatives.

The first clue to the molecular abnormality affecting the platelets of patients with this disorder (now known as the Bernard-Soulier syndrome [BSS]) came in 1969 from the work of Gröttum and Solum,2 who noted reduced electrophoretic mobility of the platelets due to a marked decrease in the concentration of sialic acid on their membranes. Subsequently, Howard et al3 and Caen and Levy-Toledano4 found that the platelets of BSS patients failed to aggregate to ristocetin, a peptide antibiotic known to aggregate normal platelets but not the platelets of patients suffering from von Willebrand disease. Weiss et al5 in 1974 extended this observation by demonstrating a defect in the ability of BSS platelets to adhere to rabbit aortic subendothelium. They also suggested that the defect resulted from absence of a receptor for von Willebrand factor (vWF) on the platelet surface. Numerous other phenotypic abnormalities have been described in BSS, including defective platelet aggregation to bovine vWF,3,6 abnormalities of membrane phospholipid content7,8 and coagulant activity,6,8 and morphological characteristics that include large size and disordered cytoskeletal structure.9,10

The nature of the missing vWF receptor was suggested in 1975 when Nurden and Caen11 demonstrated that 1 of the 3 major carbohydrate-containing proteins on the platelet surface, glycoprotein I, was virtually absent in the platelets of BSS patients. The biochemical defect was defined further in the laboratories of Clemetson et al12 and Berndt et al,13 when they demonstrated, in unrelated patients with BSS, deficiencies of 4 polypeptides: glycoproteins (GP) Ibalpha , Ibbeta , IX, and V. These polypeptides all associate on the platelet surface to form a receptor called the GP Ib-IX-V complex.

The importance of this receptor for normal hemostasis is perhaps best illustrated by the clinical history of the original patient described by Bernard and Soulier.14 As both a child and a young man, this patient suffered numerous bleeding problems, including prolonged bleeding after tooth extraction, life-threatening cerebrospinal hemorrhage, and orbital and periorbital hematomas after an accident. He died at 28 years of age of intracranial hemorrhage after a barroom brawl.

    THE GP Ib-IX-V COMPLEX: STRUCTURE AND FUNCTION

The GP Ib-IX-V complex has two important roles in platelet function that explain the often severe bleeding observed in BSS: it mediates adhesion to the blood vessel wall at sites of injury by binding vWF and it facilitates the ability of thrombin at low concentrations to activate platelets.15 The interaction with vWF underlies another potentially important function that may be more relevant to thrombosis than to hemostasis: shear-induced platelet aggregation.16 Furthermore, the GP Ib-IX-V complex may have important roles in the process by which platelets are generated and possibly in platelet turnover, as evidenced by the decreased number and abnormal size of platelets from BSS patients.

The key structural features of the GP Ib-IX-V complex are depicted schematically in Fig 1. The complex comprises 4 distinct transmembrane polypeptide subunits, GP Ibalpha , GP Ibbeta , GP IX, and GP V, with a stoichiometry based on monoclonal antibody binding of 2:2:2:1, respectively.17-20 Each of the 4 subunits is a member of the leucine-rich repeat motif superfamily, members of which are involved in such diverse processes as cell signaling, cell adhesion, and development.21,22 In the polypeptides of the GP Ib-IX-V complex, the leucine-rich repeat sequences are approximately 24 amino acids in length, occur singly or in tandem repeats, and are flanked by conserved N- and C-terminal disulfide loop structures.22 However, despite these structural similarities, the polypeptides comprising the GP Ib-IX-V complex all arise from distinct genes residing in different regions of the genome.23-27


View larger version (40K):
[in this window]
[in a new window]
  		Fig 1. Schematic view of the platelet GP Ib-IX-V complex. Key structural features of the complex are shown. The leucine-rich repeats of the four polypeptides are drawn based on the structure determined for the porcine ribonuclease inhibitor, a protein made up entirely of leucine-rich repeats.32 The depicted polypeptide arrangement is based on the published stoichiometry determined by monoclonal antibody binding17-19 and on the associations determined for the polypeptides.47,112 A caveat about this depiction: the quantity of GP V on the platelet surface has only been determined using 2 GP V monoclonal antibodies,18,20 which could lead to overestimates or underestimates of true polypeptide number. In addition, no quantitation has ever been performed to indicate that every GP V molecule on the platelet surface is associated with the complex. Complexes of greater complexity having the same stoichiometry are also possible.22,82 Diamonds on stalks represent N-linked carbohydrates and circles on stalks represent O-linked carbohydrate.

GP Ibalpha (135 kD, 610 amino acids) consists of an N-terminal globular domain28 that contains 7 tandem leucine-rich repeats and their flanking sequences, a 19-amino acid sequence rich in negatively charged aspartate and glutamate residues, and 3 sulfated tyrosines,29,30 a highly glycosylated, macroglycopeptide mucin core, a single transmembrane sequence, and a cytoplasmic tail of 96 amino acid residues.31 The structure of the leucine-rich repeats depicted in Fig 1 is based on the x-ray crystal structure of porcine ribonuclease inhibitor, a protein made up entirely of leucine-rich repeats.32 In this structure, each repeat forms a beta -alpha structural unit (a short beta -strand parallel to an alpha -helix), resulting in a horseshoe-shaped molecule in which the helices form the outer circumference and the beta -strands form the inner surface. If the GP Ib-IX-V leucine-rich repeats adopt a similar structure, this produces a fan-shaped surface with most of the amino acid side chains exposed to solvent, a property that may maximize surface interactions with target proteins and that also has the effect of bringing the flanking sequences into proximity. The macroglycopeptide contains an O-linked, sialylated hexasaccharide on average every 3 to 4 amino acids,33-35 creating a scaffold that extends the N-terminal globular domain and vWF binding site approximately 45 nm from the surface of the platelet plasma membrane.28 This region is highly polymorphic. In any individual, its length depends on which combination of 4 possible alleles is inherited. The products of these alleles differ in having 1, 2, 3, or 4 tandemly repeated copies of a 13-amino acid sequence,36,37 each of which has been predicted to add about 32 Å to the length of the macroglycopeptide.36

GP Ibbeta (25 kD, 181 amino acids) has a single leucine-rich repeat and is disulfide-linked to GP Ibalpha immediately proximal to the platelet plasma membrane.38 The cytoplasmic sequence of 34 amino acids contains a protein kinase A phosphorylation site at Ser16639 that appears to regulate platelet cytoskeletal rearrangement in response to agonist stimulation.40

GP IX (22 kD, 160 amino acids), like GP Ibbeta , has a single leucine-rich repeat motif41 and remains associated with GP Ib as a 1:1 complex when purified in Triton X-100.42 It has a short cytoplasmic tail of 5 amino acids. The cytoplasmic sequences of GP Ibbeta and GP IX both have a membrane-proximal cysteinyl residue that can be palmitoylated in vitro, a modification that may provide additional anchorage for the complex in the platelet membrane.43 Analysis of guinea pig megakaryocyte proteins suggests that GP IX is primarily myristoylated rather than palmitoylated.44

GP V (82 kD, 544 amino acids) has 15 leucine-rich repeats and a short cytoplasmic tail of 16 amino acids.45,46 It is thought to bridge adjacent GP Ib-IX complexes through an interaction with GP Ibalpha .47 The other feature of GP V is that it is one of a limited set of thrombin substrates on the platelet plasma membrane, with a major fragment, GP Vf1 (69.5 kD), released from the surface of thrombin-treated platelets.48 The functional significance of this cleavage in platelet physiology remains unclear.

The principal function of the GP Ib-IX-V complex in hemostasis is to initiate the arrest of platelets at sites of vascular injury. Like other adhesion receptors, ligation of the GP Ib-IX-V complex by vWF can transduce signals to the platelet cytoplasm, initiating the cascade of events that leads to the formation of a hemostatic platelet plug. However, unlike other adhesion receptors, the GP Ib-IX-V complex is a unique adhesive system unrelated in structure to members of the integrin, selectin, or Ig superfamilies, which mediate other aspects of blood cell-vessel wall interaction.49 The binding site for the GP Ib-IX-V complex resides within the A1 domain of vWF,50,51 included within residues 480-718 of the mature sequence.52 Mature vWF has a subunit molecular weight of 230,000 (2,050 amino acids)53 and circulates in a nonadhesive form consisting of disulfide-linked multimers of up to 20 × 106 in molecular weight.54 vWF bound to the subendothelial matrix is believed to undergo a conformational change that reveals a normally cryptic binding site for the GP Ib-IX-V complex within its A1 domain.55 vWF also binds to the GP Ib-IX-V complex under the influence of high shear forces16 by induction of conformational changes in either the receptor or vWF or in both.56,57 Consistent with this finding, gain-of-function mutations occur in both the receptor and in vWF that enhance the receptor-ligand interaction. In platelet-type (or pseudo) von Willebrand disease, mutations of GP Ibalpha (Met239right-arrowVal58 or Gly233right-arrowVal59) result in a receptor complex with higher affinity for circulating vWF.60,61 In type 2B von Willebrand disease, point mutations in the vWF A1 domain clustered around the Cys509-Cys695 disulfide bond and between Met540 and Arg578 yield a form of vWF with enhanced avidity for the native GP Ib-IX-V receptor on platelets.62 A number of modulators have been identified that also enhance the interaction between vWF and the GP Ib-IX-V complex.63 These include the antibiotic ristocetin, from the gram-negative bacterium Nocardia lurida, which appears to function, at least in part, by binding to proline-rich sequences flanking the disulfide bond between Cys509 and Cys695 in the vWF A1 domain.64-66 A second modulator, botrocetin (a disulfide-linked heterodimer of 28 kD from the venom of the South American pit viper, Botrops jararaca) activates vWF adhesive function towards platelets by binding to noncontiguous sequences within the A1 domain loop.66,67

The regions involved in the binding of vWF to GP Ibalpha have only been partially defined and appear to be dependent, in part, on conformational structure in both the ligand and receptor. In vWF, both the peptide sequence, Asp514 to Glu542,66 and the region encompassing Glu596 and Lys59968 have been proposed as receptor recognition sites. In GP Ibalpha , the vWF binding site is located within the N-terminal approximately 300 amino acids.30,69,70 Three regions within this domain appear to be important for vWF binding (Fig 2). One corresponds to the anionic sulfated-tyrosine sequence,29,30,71,72 which appears to be preferentially involved in botrocetin-dependent binding of vWF.30,71 Sulfation of tyrosine residues in this sequence is more critical for botrocetin-dependent than for ristocetin-dependent binding of vWF,72 but both modulators require the modification for optimum effect. An Escherichia coli-produced GP Ibalpha fragment containing the sequence encompassing Gln221-Leu318 has been reported to contain the ristocetin-dependent binding site for vWF, with a disulfide-bond between Cys248 and Cys264 critical for function.73 Because Cys248 and Cys264 are normally disulfide-bonded to Cys209 and Cys211, respectively,74 the significance of this finding is not clear. The leucine-rich repeats also appear to have an important role in vWF binding, as suggested by studies of BSS patients who express mutant GP Ib-IX-V complexes on their platelets. Platelets expressing these mutant complexes, which both result from mutations in the GP Ibalpha leucine-rich repeats (Leu47right-arrowPhe75 and Ala156right-arrowVal76), bound vWF less efficiently than did normal platelets. Finally, two gain-of-function mutations (Gly 233right-arrowVal59 and Met 239right-arrowVal58) in platelet-type von Willebrand disease are located in the flanking sequence C-terminal to the leucine-rich repeats.22 Both of these mutants spontaneously bind vWF in the absence of ristocetin, botrocetin, or shear, implying that this domain may be directly involved in vWF binding or could regulate that function.


View larger version (17K):
[in this window]
[in a new window]
  		Fig 2. The GP Ibalpha N-terminus with the regions shown to be important for vWF binding. Asterisks indicate that the tyrosines are sulfated.

Available evidence indicates that the GP Ib-IX-V-vWF interaction may in many ways be similar to the interaction between selectins and their ligands. Similar to the rolling of leukocytes mediated by selectins, recent observations indicate that the GP Ib-IX-V complex can mediate translocation of platelets along a surface coated with vWF. Such a phenomenon requires that the bonds be able to form and break rapidly. In the studies of Savage et al,77 the vWF-GP Ib-IX-V interaction could slow the platelets in this way, but a further interaction between vWF and the GP IIb-IIIa complex was required to fully arrest the platelets. As yet, it is unclear how this in vitro phenomenon relates to the situation in vivo, because vWF in the environment of the subendothelium may adapt a different conformation than when immobilized on glass. The influence of vWF conformation on platelet translocation was nicely demonstrated in the studies of Moroi et al78 (in a system similar to that of Savage et al77), who demonstrated that addition of botrocetin to vWF immobilized on glass markedly decreased platelet translocation, presumably because it increased the affinity of the interaction.

Thrombin also binds within the N-terminal sequence, His1-Glu282, of GP Ibalpha , specifically to the anionic sulfated-tyrosine sequence.30,79 Thrombin recognition, in contrast to the binding of vWF, has a greater stringency requirement for tyrosine sulfation in that all 3 tyrosine residues must be sulfated for effective binding of thrombin to GP Ibalpha .72 High-affinity binding to the GP Ib-IX-V complex may also involve recognition of segments of the leucine-rich repeat C-terminal flanking sequence80,81 and GP V.82 Although the agonist action of thrombin towards platelets primarily involves signaling through the 7-transmembrane PAR-1 and/or PAR-3 thrombin receptors,83,84 binding of thrombin to the GP Ib-IX-V complex facilitates the platelet response to low concentrations of thrombin.85-87 A defective response to thrombin undoubtedly contributes to the bleeding diathesis of patients with BSS. A detailed discussion of the nuances of thrombin's association with the GP Ib-IX-V complex is beyond the scope of this review. The interested reader is referred to the recent review of Jamieson.88

Although it is unknown how thrombin signals through the GP Ib-IX-V complex, there is increasing evidence that ligation of vWF initiates signaling events that result ultimately in inside-out activation of the integrin, GP IIb-IIIa, and platelet aggregation.16,89 Signaling by other adhesion receptors can be initiated by receptor cross-linking90; recent evidence suggests that a similar mechanism may be operative in GP Ib-IX-V-dependent signaling in platelets. First, a monomeric 39/34-kD proteolytic fragment of vWF is able to bind to the GP Ib-IX-V complex and inhibit binding of multimeric native vWF, but does not activate platelets.52 Second, GP Ibalpha is arranged on the cell surface as part of a larger receptor complex, with two or more GP Ibalpha subunits forming a cluster with the other glycoproteins of the complex.22 Third, GP Ibalpha is associated via its cytoplasmic region with actin-binding protein and 14-3-3zeta protein (see below and Fig 1), both of which form noncovalent dimers. Finally, the 50-kD (presumably bivalent) viper venom protein, alboaggregin, binds to GP Ibalpha and activates platelets, whereas structurally related monomeric 25-kD venom proteins bind to the same domain on GP Ibalpha , but do not activate platelets.91

The signaling events induced by vWF binding to GP Ib-IX-V in the presence of shear, ristocetin, or botrocetin include elevation of cytosolic Ca2+ and activation of protein kinases.92-95 Ser/Thr protein kinases become activated, as 2 of their substrates, pleckstrin and the myosin light chain, are rapidly phosphorylated.92 Two major tyrosine kinase substrates (~76 and ~36 kD) also become phosphorylated,92 but the identity of neither is known.95 Interestingly, both species are also phosphorylated in response to 50-kD alboaggregin.91 Other consequences of vWF binding to GP Ib-IX-V include association of activated phosphatidylinositol 3-kinase (PI 3-kinase) and src with the cytoskeleton,94 breakdown of phosphatidylinositol 4,5-bisphosphate, generation of phosphatidic acid, activation of phospholipase A2, and synthesis of arachidonic acid and thromboxane A2.92

One of the interesting features of the GP Ib-IX-V complex is that none of the cytoplasmic sequences of its 4 constituent polypeptides contains motifs known to interact with signaling proteins. Nevertheless, these regions do interact with proteins of the platelet membrane cytoskeleton, providing a potential means for the complex to transduce activation signals. The cytoplasmic domain of GP Ibalpha contains a binding site for actin-binding protein within the sequence Thr536 to Leu554.96 This association with actin-binding protein links the complex with a network of short submembranous actin filaments.97,98 This membrane skeleton of quiescent platelets contains other cytoskeletal proteins, including spectrin, dystrophin, talin, vinculin, and protein 4.1, and several signaling proteins, including the tyrosine kinases src, yes, and syk, the small G protein, p21 ras, and the tyrosine phosphatase, SHP 1.99-101 In unstimulated platelets, much of the GP IIb-IIIa complex is also attached to the membrane skeleton,99 suggesting that one of the functions of this structure may be to preassemble key signaling elements, allowing transmission of signals after GP Ib-IX-V ligation, eventually leading to GP IIb-IIIa activation. Consistent with a role for cytoskeletal attachment in GP Ib-IX-V functions, recent studies show that even small C-terminal truncations of GP Ibalpha greatly increase the mobility of the complex within the plane of the plasma membrane and decrease its ability to bind vWF.102

A second possible mechanism by which the GP Ib-IX-V complex may transmit signals derives from the recent finding that its cytoplasmic domain contains binding sites for the zeta  isoform of 14-3-3.103,104 Although platelet 14-3-3zeta was originally reported to have phospholipase A2 activity,105 this enzymatic activity was not found in other studies.106 Rather, 14-3-3 proteins have recently been shown to regulate the activity and assembly of key signaling molecules that, in turn, regulate such diverse processes as mitogenesis, cell cycling, vesicular transport, and apoptosis. Proteins reported to bind 14-3-3 include the cell death agonist BAD, raf-1, bcr, cbl, PKCepsilon , PKCgamma , the cdc25a and cdc25b phosphatases, the p85 subunit of PI 3-kinase, tyrosine hydroxylase, tryptophan hydroxylase, and ADP ribosyltransferase.107-109 The 14-3-3 protein family consists of a number of closely related isoforms with subunit molecular weights of approximately 30 kD that form highly stable homodimers and heterodimers.107 This latter property allows them to bridge and assemble cytoplasmic proteins containing 14-3-3 recognition motifs. The 14-3-3 isoform most commonly identified as binding signaling molecules is 14-3-3zeta .107

Recent analysis of 14-3-3 binding to raf-1 has identified 2 nonoverlapping binding sites for 14-3-3 within raf-1.108 Both sites contain serines within a conserved R S X S X P motif, a motif also found in other 14-3-3 binding proteins, including PKCepsilon , cdc25b, bcr, and BAD. The binding of 14-3-3 to these sites is regulated by phosphorylation, with the presence of phosphate on the serine favoring binding. Within the GP Ib-IX-V complex, a major binding site for 14-3-3zeta corresponds to the 4 C-terminal amino acids of GP Ibalpha , Gly-His-Ser-Leu.104,110 Additional binding sites have been identified by analysis of overlapping peptides corresponding to the cytoplasmic sequences of GP Ibalpha , GP Ibbeta , GP IX, and GP V.110 These include the central region of the GP Ibalpha cytoplasmic domain (Arg557-Gly575) and the entire cytoplasmic tail of GP V. Another binding site for 14-3-3zeta encompasses the PKA phosphorylation site in GP Ibbeta . Serine phosphorylation of a synthetic peptide containing this sequence increased its affinity for 14-3-3zeta . This effect of phosphorylation on a 14-3-3zeta -binding sequence in GP Ibbeta suggests an additional effect of PKA-dependent phosphorylation on regulating platelet activation. Because GP Ibbeta phosphorylation specifically inhibits actin polymerization,40 the increased affinity for 14-3-3zeta is consistent with a role for this protein in the control of this process. Whether 14-3-3zeta is involved in mediating the assembly of signaling complexes in response to vWF ligation of the GP Ib-IX-V complex remains to be determined.

    SYNTHESIS OF THE GP Ib-IX-V COMPLEX

GP Ibalpha , Ibbeta , and IX exist in equal numbers on the surfaces of platelets17 and cells transfected with the cDNAs encoding the 3 polypeptides.111 Only half as many molecules of GP V are found on platelets,18,19 although the preciseness of this molar relationship with the rest of the complex requires further characterization. Based on studies using both transfected cells47,111-113 and the platelets of BSS patients with different mutations,114-116 it appears that maintenance of this stoichiometry relies primarily on the relative instability of partial complexes and single polypeptides. For example, in studies of GP Ibalpha surface expression in transfected cells, it was shown that this polypeptide is expressed on the surface of the cells most efficiently when both GP Ibbeta and GP IX were cotransfected.111 Cotransfection with GP Ibalpha of less than the full complement of the other 2 polypeptides did not completely prevent GP Ibalpha expression, but did decrease it substantially. None of these 3 polypeptides is expressed efficiently on the cell surface unless expression in the cells is increased by manipulations such as gene amplification.112,117 Combinations of 2 polypeptides are more efficient in reaching the cell surface than single polypeptides if the 2 polypeptides interact with each other directly.112 GP V is not necessary for efficient expression of the rest of the complex and has only a minor effect, at most, on the expression of GP Ib-IX.47,118,119 It is the only 1 of the 4 complex polypeptides that can be efficiently expressed alone on the surfaces of transfected cells, although its surface expression is increased in the presence of the rest of the complex.47 From these studies, it was suggested that BSS could be caused by mutations of either GP Ibalpha , GP Ibbeta , or GP IX, but the typical syndrome was unlikely to be caused by mutations of GP V.47,111,112

The molecular defects characterized thus far in patients with BSS support the findings from these in vitro studies in that mutations responsible for BSS have only been shown to involve the genes for GP Ibalpha , GP Ibbeta , and GP IX (Table 1). Mutations of the latter 2 polypeptides apparently cause the disorder by decreasing surface expression of GP Ibalpha .114,115,121 In several of the cases described, residual quantities of the unaffected polypeptides are still found in the platelets.114,116,122

 
View this table:
[in this window] [in a new window]
  		Table 1. Clinical Profiles of BSS Patients

Studies in transfected cells have also proved useful for determining how the polypeptides interact with each other. From such studies, it has been demonstrated that GP Ibalpha and GP Ibbeta are able to interact in the absence of the other polypeptides, as are GP Ibbeta and GP IX.112 Thus, GP Ibbeta is the polypeptide bridging the interaction between GP Ibalpha and GP IX, at least initially, because no interaction between the later 2 polypeptides could be detected in the absence of GP Ibbeta . In contrast, antibody inhibition studies of platelet lysates and purified GP Ib-IX complex suggest that GP IX is more strongly associated with GP Ibalpha than with GP Ibbeta .123 Confocal microscopy and expression studies indicate that the interaction of GP V with GP Ib-IX is through a direct link with GP Ibalpha .47 This association has a direct functional consequence, because expression of GP V in cultured cells is required for the complex to bind thrombin with high affinity, even though the site of thrombin binding is on GP Ibalpha .82

The polypeptides of the complex all associate soon after their synthesis and insertion into the membrane of the endoplasmic reticulum.124 Before the complex reaches the cell surface, which in cultured cells takes approximately 3 hours,124 its polypeptides undergo a number of posttranslational modifications, including the addition of both N- and O-linked carbohydrate, modification of the intracytoplasmic cysteines of GP Ibbeta and GP IX by acylation with fatty acids, and sulfation of tyrosines in the ligand-binding domain of GP Ibalpha . These modifications are all likely to influence the functions of the complex, and it is probable that mutations that disrupt any of the posttranslational modifications in vivo will result in variant forms of BSS.

    GENES ENCODING THE GP Ib-IX-V POLYPEPTIDES

A separate gene encodes each component of the GP Ib-IX-V complex receptor. Like the polypeptides of this complex, the genes share a number of structural features (Fig 3). All except the gene for GP Ibbeta contain the entire coding sequence within one exon45,125,126; the GP Ibbeta gene contains an intron 10 bases after the start of the coding sequence.25 All are also relatively devoid of introns, with only the GP IX gene containing more than 1 (it contains 2).126 These genes share this compact structure and paucity of introns with other genes of the leucine-rich repeat family, the best example being the gene for oligodendrocyte-myelin glycoprotein, which contains one small intron in its 5' untranslated region and the entire coding region in 1 exon.127 Despite their structural similarity, the genes encoding the GP Ib-IX-V polypeptides are not clustered in 1 region of the human genome. The GP Ibalpha gene is located on the short arm of chromosome 17,23 the GP Ibbeta gene is on the long arm of chromosome 22,24 and the GP IX and GP V genes are located on the long arm of chromosome 327 (3q21 and 3q29, respectively; Fig 3).


View larger version (7K):
[in this window]
[in a new window]
  		Fig 3. Structures of the genes encoding the 4 polypeptides of the GP Ib-IX-V complex with exons shown as boxes, introns as the lines between boxes, and open reading frames in black. The position of the ATG start codon is also indicated.

Expression of the GP Ib-IX-V complex is limited to a very small number of tissues, the only major constitutive expression being in megakaryocytes and platelets. This complex may also be expressed in endothelial cells, although this is a matter of controversy. There have been reports of low level expression of GP Ibalpha in endothelial cells,128,129 expression that can be enhanced by the inflammatory cytokine, tumor necrosis factor-alpha .130,131 Further evidence for expression of GP Ibalpha in endothelium was obtained by the cloning of a GP Ibalpha cDNA from an endothelial cell library.131 This cDNA was virtually identical to the original GP Ibalpha cDNA cloned from a HEL cell library.31 More recently, Wu et al20 have provided evidence that endothelial cells, in culture and in vivo, express the full GP Ib-IX-V complex. One difference with the platelet complex is in the nature of GP Ibbeta . Kelly et al24 found a polypeptide in endothelial cells that reacted with GP Ibbeta antisera, but that migrated at a higher molecular mass (~50 kD) than the platelet polypeptide (~25 kD). They also cloned a cDNA that encoded a polypeptide with an amino terminus unrelated to platelet GP Ibbeta but fused in frame with the platelet sequence such that the new polypeptide also contained essentially all of the platelet sequence. This interpretation of the data has since been challenged by Zieger et al,132 who also cloned a cDNA containing the GP Ibbeta sequence. They identified a new gene immediately 5' to the GP Ibbeta gene that produced 2 transcripts, 1 containing the GP Ibbeta sequence. The latter transcript presumably arose because the 5' gene contains a suboptimal polyadenylation sequence. Hence, the transcription machinery sometimes reads through it and into the GP Ibbeta gene, eventually using the GP Ibbeta polyadenylation sequence. The resulting transcript thus also contains the GP Ibbeta sequence, albiet out of frame, a finding at odds with that of Kelly et al.24

One potential function for the complex expressed in endothelial cells derives from the work of Beacham et al,133 who suggested that the complex can mediate attachment of endothelial cells to vWF. Bombeli et al134 also recently proposed a role for endothelial cell GP Ibalpha in adhesion of activated platelets to umbilical vein endothelial cells. Others have not been able to demonstrate GP Ib-IX-V-mediated attachment of endothelial cells to vWF and have even called into question whether these cells have significant levels of complex expression.135 If, how, and when the GP Ib-IX-V complex is expressed in endothelial cells are thus still open questions in need of more investigation. Such expression of the GP Ib-IX-V complex in endothelium in vivo may depend on such variables as regional shear stresses, the presence of inflammatory cytokines, and the particular vascular bed from which the cells are derived.

At least part of the restricted expression of the GP Ib-IX-V complex can be ascribed to the unusual structure of the promoter regions of its genes. None of the promoters contain functional TATA or CAAT boxes, consensus transcription factor-binding sequences found in a high percentage of eukaryotic genes (GP V does contain 2 potential TATA boxes, but primer-elongation studies did not show transcripts of the expected sizes45). Instead, these promoters contain binding sites for the GATA and ETS families of transcription factors, a feature shared with other genes expressed in cells of megakaryocytic and erythroid lineages.136-142 Neither GATA nor ETS is specific for megakaryocytes; it has been suggested that particular combinations and relative levels of the GATA and ETS families are what determine megakaryocyte specificity.138,140 This specificity may also be related to transcriptional cofactors. Recently, a transcription factor named FOG (Friend of GATA-1) was described, which acts as a cofactor for GATA-1 during both erythroid and megakaryocytic cell differentiation.143 Together, the 2 transcription factors may stimulate transcription in a context-specific manner.144

The importance of these factors for transcription of the GP Ib-IX-V genes is demonstrated by both synthetic and natural mutations. Mutations of both the GATA and ETS binding sequences in the promoters of GP Ibalpha and GP IX have been shown to reduce or abolish reporter gene expression in human erythroleukemia cells.141,142 Likewise, a single-base mutation of the GATA-1 site in the GP Ibbeta promoter markedly reduced expression of GP Ibbeta and caused BSS in a patient with deletion of the other GP Ibbeta allele and velo-cardio-facial syndrome.115

    POLYMORPHISMS AFFECTING THE GENES AND POLYPEPTIDES OF THE GP Ib-IX-V COMPLEX

Several polymorphisms of the GP Ib-IX-V complex have been described, affecting primarily the GP Ibalpha gene. In addition to potentially affecting the structure and functions of the complex, these polymorphisms serve as useful linkage markers for the genes affected.

The first described polymorphism of the complex was a variable number of tandem repeats (VNTR) polymorphism affecting the region encoding the GP Ibalpha macroglycopeptide.36,37,145,146 The 4 alleles vary in the number of tandem repeats of a 39-nucleotide sequence, which is present either 1, 2, 3, or 4 times in the different alleles.36,37 The resulting polypeptides specified by these alleles contain different numbers of 13-amino acid repeats in their macroglycopeptide region. Each repeat contains 5 potential sites for O-glycosylation, a modification predicted to add approximately 6 kD to the mass of the macroglycopeptide and 32 Å to its length.36 This VNTR polymorphism is the most informative as a genetic marker because of the high frequency of heterozygosity at this locus (25% to 30% in most populations).36 The frequencies of the different alleles vary widely in different ethnic populations, although the variant with 2 repeats (C variant) is the most common in all populations studied.22

Another polymorphism of GP Ibalpha results in dimorphism at residue 145, with either Thr or Met occupying this position. The allele frequencies have been reported to be 90% and 10%, respectively, for the Thr and Met codons in both European and Japanese populations.147,148 This marker is closely linked to the VNTR polymorphism, with Met at position 145 being found only associated with the 3 largest size variants.37,149,150 Thus, this marker might be of use in determining heterozygosity in someone homozygous for the larger VNTR alleles. This marker has the additional advantage that the products of its alleles can be recognized on platelets with antisera, because this polymorphism accounts for the HPA-2 (or Ko) alloantigen system.147,148

Recently, 2 more polymorphisms of the GP Ibalpha locus were described, the RS system, its alleles specifying either C or T at position -5 from the ATG start codon,151 and a nucleotide dimorphism (A or G) of the third base of the codon for Arg358.151,152 The degree of association between these markers and the other GP Ibalpha polymorphisms has yet to be determined.

To analyze for possible linkage of the BSS phenotype with the GP Ibbeta locus, markers used in the analysis of the Di George and velo-cardio-facial syndromes can be used.153-156 As yet, no markers are available for the GP IX or GP V genes.

    BSS: CLINICAL MANIFESTATIONS, DIAGNOSIS, AND THERAPY

BSS is extremely rare. In the populations of Europe, North America, and Japan, which have been studied most intensively, a prevalence of less than 1 in 1,000,000 can be estimated from cases reported in the literature. No doubt, this is an underestimate due to misdiagnosis and underreporting, but the low frequency of reported cases nevertheless is an indication of the rarity of the disorder. Perhaps one reason for this low prevalence is that, despite the potential for the disorder to be caused by mutation of any of 3 genes (and perhaps 4), the compactness of these genes decreases the frequency at which they are subject to random mutation. The lack of introns interrupting the coding sequence also greatly decreases the possibility that missplicing will cause deficiency of the encoded polypeptides. The low frequency of mutation at these loci is reflected also in the fact that the majority of the reported cases are homozygous for the same allele, having inherited 2 mutant alleles from parents who are blood relatives. The clinical features of the BSS patients reported to date are summarized in Table 1. Based on this relatively small number of reported cases, there appears to be no gender preference for BSS (47 of 88 patients described in Table 1 are female), as one would expect from an autosomal disorder. Of the patients in Table 1 for whom ethnicity was reported, 49 are Caucasian, 13 are Japanese, and 4 are of other ethnic groups.

Inheritance.   Inheritance of the BSS is usually autosomal recessive and is often associated with consanguinity (Table 1). Heterozygous family members may show about half the normal levels of platelet GP Ib-IX-V expression, but with no bleeding diatheses or only mild bleeding. Autosomal dominant inheritance has been reported in only 1 family.75

Clinical manifestations.   BSS is characterized clinically by a prolonged skin bleeding time, morphologically enlarged platelets, and thrombocytopenia (Table 1 and reviewed in Dunlop et al157). Clinical manifestations commonly include frequent episodes of epistaxis, gingival and cutaneous bleeding, and hemorrhage associated with trauma. Although these characteristics are typical, comparisons of the clinical profiles of BSS patients reveal considerable variation between individuals. Platelet counts may range from very low (<30,000/µL) to marginally low or normal (~200,000/µL) and in individual patients may fluctuate considerably over a period of years. Skin bleeding times may range from only marginally prolonged (5 to 10 minutes) to greater than 20 minutes. Bleeding tendencies associated with BSS are usually evident from early childhood. However, the severity of symptoms may progressively worsen or become alleviated throughout puberty and adult life. Most often, severe bleeding episodes are associated with tonsillectomy, appendectomy, splenectomy, other surgical procedures, dental extractions, menses and pregnancies, or accidents. Ecchymoses without significant trauma are relatively common, as are episodes of spontaneous epistaxis and gingival and gastrointestinal bleeding. Menorrhagia in premenopausal women is of variable severity and may be controlled in some cases by oral contraceptives.13,158,159 Pregnancy in BSS patients may be relatively uneventful or may present complications of varying severity.116,121,122,158,160-166 Bleeding associated with childbirth is generally supported by blood and/or platelet transfusions and may necessitate hysterectomy to control bleeding.161 Multiple childbirth is not uncommon.116,121

Diagnosis.   Congenital platelet disorders related to platelet adhesion, activation, secretion, aggregation, or number and various coagulopathies are often not distinguishable from their clinical manifestations alone, presenting a challenge to diagnosis that often requires specialized tests or biochemical analyses. For example, BSS has frequently been misdiagnosed as idiopathic thrombocytopenic purpura (ITP),116,121,167-170 based on a prolonged bleeding time and thrombocytopenia, and often is treated unsuccessfully with steroids or splenectomy. The initial laboratory assessment of BSS should involve measurement of blood cell counts and examination of a blood smear for thrombocytopenia and morphological abnormalities of platelets. BSS can usually be differentiated experimentally from other bleeding disorders by functional analysis of stirred platelet suspensions in an aggregometer. The characteristic abnormality in BSS is an isolated defect in ristocetin-induced agglutination. Unlike the defect in von Willebrand disease, this abnormality is not corrected by the addition of normal plasma. Platelet aggregation in response to other agonists, such as collagen and ADP, as well as clot retraction, is usually normal. The provisional diagnosis based on aggregometry should be confirmed biochemically (reviewed in Dunlop et al157). This may involve assessment of platelet surface glycoprotein expression by flow cytometry, surface-labeling of washed platelets followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography, or immunoblotting of platelet lysates with specific antiplatelet glycoprotein antibodies. Finally, establishing an abnormal genotype by molecular studies may allow precise definition of the abnormality causing the platelet defect, as discussed below.

Therapy.   The therapeutic approaches to the management of patients with BSS involve both general supportive measures and specific treatment of bleeding episodes. General measures include educating the patients about their bleeding diathesis and the importance of avoiding even relatively minor trauma and advising them against the use of antiplatelet medications such as aspirin. Adequate dental hygiene should be maintained to prevent gingival disease and to minimize dental procedures. Iron deficiency may result from chronic gingival bleeding or menorrhagia and should be treated. In some cases, splenectomy has apparently been beneficial in moderating thrombocytopenia and the severity of clinical symptoms,158,168,171,172 although this treatment should be avoided because of the high risk for perisurgical hemorrhage and the lack of controlled data to support its use. Control of bleeding episodes or prophylaxis for prevention of bleeding during surgical procedures usually requires transfusion of blood and/or platelets, despite the risk that these patients will develop antiplatelet and/or antierythrocyte alloantibodies.158,168,171,172 General anesthesia has been successful in a BSS patient, although anesthetics such as halothane or dibucaine that compromise platelet reactivity should be avoided.173 The use of antifibrinolytic drugs, such as epsilon -aminocaproic acid or tranexamic acid, may or may not be beneficial.169,170,172 DDAVP may shorten the bleeding time in some168,171,174 but not all159,169 BSS patients. The different responses of individual patients to these latter measures may reflect differences in the underlying disease, with those with milder forms of the disease more likely to respond to these therapies.

Because of the relative ease with which the molecular lesions can be determined and given the simplicity of the affected genes, BSS seems an ideal candidate disease for gene therapy. Such therapy would presumably involve transduction of a hematopoietic stem cell with a working copy of the defective gene, under the control of its own promoter or of another platelet-specific promoter. Among the questions to be answered before such therapy becomes reality is whether reconstituting the blood with only a relatively small proportion of normal platelets will be sufficient to ameliorate the bleeding diathesis associated with BSS.

    BSS: CLASSIFICATION

The genetic defects underlying BSS so far determined (Table 1) are clearly heterogeneous, but may be broadly categorized in 2 ways. First, the abnormality may be either (1) a biosynthetic defect affecting synthesis, processing, or expression of the GP Ib-IX-V complex; or (2) a functional defect in which GP Ibalpha is expressed in a dysfunctional form that fails to bind ligand. Second, the genetic lesion may be localized to (1) the GP Ibalpha gene (chromosome 17pter-p12), (2) the GP Ibbeta gene (chromosome 22q11.2), (3) the GP IX gene (chromosome 3q21), or possibly (4) the GP V gene (chromosome 3q29). The syndrome may conveniently be classified, therefore, as type 1a to indicate a defect of the GP Ibalpha gene that results in a biosynthetic defect, type 1b for a synthetic defect of the GP Ibbeta gene, etc. The molecular defects thus far reported arise from missense, nonsense, or deletion mutations of the GP Ibalpha , GP Ibbeta , or GP IX genes (Table 1) that produce truncated, unstable, or dysfunctional polypeptides.

    INFORMATIVE MUTATIONS IN BSS AND PLATELET-TYPE VON WILLEBRAND DISEASE

Clearly, much remains to be learned about the cause of several phenotypic features of the BSS. Nevertheless, elucidation of the molecular basis of BSS and platelet-type von Willebrand disease has provided several very valuable insights into the synthesis and functions of the complex. A few of the more informative mutations will be reviewed in this section.

GP Ibalpha mutations.   Several mutations of GP Ibalpha provide interesting information regarding the functions of the GP Ib-IX-V complex. The Bolzano variant of BSS, caused by a substitution of Val for Ala at position 156 of GP Ibalpha , produces mutant complexes that appear on the cell surface essentially at normal levels.76 This mutant is unable to bind vWF normally, but binds thrombin with a similar affinity to that of the wild-type complex.175 The platelets of the patient with the Bolzano variant of BSS thus do not have the defect in the response to low concentrations of thrombin that most BSS platelets do. This finding suggests that the leucine-rich repeats have an important role in binding vWF, but not thrombin. Another interesting feature of this mutant is that it has no mutations of its cytoplasmic region that would be predicted to influence the association of the complex with the platelet cytoskeleton, yet the platelets of the affected patient are much larger than normal, indicating that the large platelets in BSS cannot be explained simply by a defective membrane-cytoskeletal association.

Only one instance of autosomal-dominant transmission of BSS has been described. The responsible mutation, Leu57right-arrowPhe, like the Bolzano mutation, affects the leucine-rich repeat region of GP Ibalpha and encodes a mutant polypeptide that appears on the cell surface, but, once there, is apparently abnormally susceptible to cleavage by plasma proteases.75 The dominant nature of this mutation suggests that the product of the mutant allele interferes with the functions of the wild-type polypeptide, giving further support for the existence of a vWF receptor containing more than 1 GP Ibalpha polypeptide.

Also of interest is the recently described deletion of the last 2 bases of GP Ibalpha codon 492, which results in a reading frame-shift within the region encoding the GP Ibalpha membrane-spanning segment, with the addition of 81 novel amino acids before the polypeptide reaches a premature stop. Two unrelated patients homozygous for this mutation were described simultaneously; both had a considerable amount of GP Ibalpha or a degradation product in their plasma, indicating that GP Ibalpha was synthesized normally but failed to be anchored in the plasma membrane.120,176 In addition to carrying the same mutation, these 2 patients had an identical haplotype, with identical sequences at 3 other polymorphic sites. The ancestors of both of these patients emigrated to the United States from Germany. Interestingly, a Finnish patient carrying an identical mutant haplotype was recently reported in abstract form.177 This mutant haplotype probably arose at least several centuries ago in the northern European population and will likely be a common mutation associated with the disorder in patients of northern European ancestry.

Platelet-type von Willebrand disease is another bleeding disorder caused by mutations affecting the GP Ib-IX-V complex, but in this case resulting in a dominant gain-of-function phenotype.60,61 The resultant mutants bind vWF with high affinity and the paradoxical presence of a bleeding predisposition is due to clearance of the hemostatically most active large vWF multimers. The mutations described in this disorder (Gly233right-arrowVal59 and Met239right-arrowVal58,178,179) are found within a short linear sequence encompassing residues 233 to 239 of GP Ibalpha , a region that lies within the loop formed by a disulfide bond between Cys209 and Cys248 of GP Ibalpha (Fig 2). Molecular modeling studies of this region suggest that the mutations produce an active conformation of GP Ibalpha that is competent to bind vWF in the absence of modulators.180,181 These mutants thus provide clues as to changes that the receptor undergoes when platelets are exposed to shear or ristocetin.

GP Ibbeta .   Two BSS variants that result from mutations of GP Ibbeta are particularly informative. The first was described in a patient with velo-cardio-facial syndrome, a developmental disorder caused by deletion of the chromosomal region 22.11.2, which contains the gene for GP Ibbeta .182 This patient's remaining GP Ibbeta gene did not contain any mutations in the polypeptide coding region, but a single point mutation was found in the promoter region within a binding sequence for the GATA-1 transcription factor.115 Transcription studies performed in cell lines demonstrated that the mutation decreased the transcription of a reporter gene sixfold. So far, this is the only reported case of BSS not caused by mutations of polypeptide coding regions.

Another interesting variant of BSS caused by mutations of the GP Ibbeta gene was described in a Japanese patient with a very mild propensity for bleeding.183 This patient was a compound heterozygote for 2 mutations (Tyr88right-arrowCys and Ala108right-arrowPro). The platelets were not defective for agglutination by either ristocetin or botrocetin and had only slightly decreased surface levels of the GP Ib-IX-V complex. This patient's platelets were very large, and the only finding that could explain this abnormality was the failure of the normal disulfide linkage between GP Ibalpha and GP Ibbeta , suggesting that the mutant complexes may have a signalling defect.

GP IX.   BSS caused by mutations in the gene for GP IX emphasize the importance of this polypeptide in the synthesis and surface expression of the entire GP Ib-IX-V complex. The first case of BSS reported to be due to such mutations was described by Wright et al114 in 3 siblings who were compound heterozygotes for mutations in the GP IX gene. Both alleles were affected by missense mutations of the GP IX leucine-rich repeat region (Asp21right-arrowGly and Asn45right-arrowSer), and the expression of the entire complex on the surfaces of their platelets was minimal. Expression of the mutants in cultured cells showed that both mutant polypeptides failed to associate with GP Ibbeta or augment expression of GP Ib (alpha -beta ) on the cell surface, suggesting a role for the GP IX leucine-rich motif in polypeptide associations.184

Bernard-Soulier variants.   In addition to the disorder produced by germline mutations, acquired BSS from somatic mutation of bone marrow stem cells has also been described. Two cases have been described in association with myelodysplasia (both in children),185,186 and 1 case was described in a patient with acute myelogenous leukemia (M6).186 In 1 patient with a myelodysplastic syndrome and monosomy 7, 2 populations of platelets were identified in her blood, 1 population of normal-sized platelets with normal levels of the GP Ib-IX-V complex on their surfaces and 1 of large platelets lacking the complex.185 The latter population was apparently produced by the abnormal marrow clone. This patient died of acute leukemia shortly after acquiring the disease.

BSS-like defects are also rarely seen associated with immune thrombocytopenia when the offending antibody interferes with vWF binding to the GP Ib-IX-V complex.187-189 In this situation, the bleeding risk is much greater than usually seen in immune thrombocytopenia because the hemostatic defect resulting from the low platelet count is compounded by the severe adhesive defect of the platelets that remain in circulation.

    UNEXPLAINED PHENOMENA IN BSS

BSS platelets have several phenotypic features that remain poorly understood. One is their large size. An obvious explanation for this feature is provided by the altered plasma membrane-cytoskeletal interaction due to the absence of the GP Ib-IX-V complex on the platelet surface. Although this defect undoubtedly explains the increased deformability of the Bernard-Soulier platelet membrane,190 it may not be the cause of the abnormally large platelets in this syndrome. Several BSS patients have been described whose platelets are large but contain relatively normal surface levels of the complex. In 1 of these, the Bolzano variant, the GP Ibalpha polypeptide contains only a single amino acid substitution in its extracellular domain that affects vWF binding but not surface expression of the complex. These platelets presumably have a normal linkage with the cytoskeleton, although the possibility remains that the mutation changes the conformation of the cytoplasmic domain and influences that association.

These data would also seem to suggest a role for vWF binding in platelet production from megakaryocytes; however, such a role is ruled out by the observation that patients with severe (type 3) von Willebrand disease have normal-sized platelets. Consistent with this, another BSS variant with defective GP Ibalpha -GP Ibbeta chain association produces large platelets and has relatively normal expression of the complex and vWF binding.183 These data suggest that the abnormality in BSS platelets that leads to their abnormal size may either be the failure of the GP Ib-IX-V complex to recognize a novel bone marrow ligand involved in platelet shedding or a disruption of the signalling pathways involved in this process. In this regard, BSS platelets have been reported to have decreased levels of phospholipase C activity.191

The second phenotypic characteristic of BSS that has yet to be fully explained is the abnormality of the prothrombin consumption test in BSS platelets.192 The prothrombin consumption test detects deficiencies of factors V, VIII, IX, XI, or XII,193 more than 1 of which could contribute to the abnormality of this test in BSS. Accordingly, BSS platelets have been reported to be deficient in collagen-induced coagulant activity and to be unable to bind factor XI.6 In addition, the GP Ib-IX-V complex has recently been reported to be the platelet binding site for high molecular weight kininogen194 and for factor XII.195 Finally, the abnormal prothrombin consumption test with BSS platelets has been reported to be correctable by the addition of factor VIII. This latter finding is consistent with the GP Ib-IX-V complex providing a low-affinity receptor on platelets for vWF/factor VIII, a conjecture consistent with the observation that treating normal platelets with an anti-GP Ibalpha antibody that blocks vWF binding mimics the abnormality in the prothrombin consumption test seen in BSS platelets.196 In contrast to the abnormality in the early stages of contact activation, resting BSS platelets show enhanced prothrombinase activity8 due to increased levels of phosphatidylserine on their surfaces.

    STRATEGIES FOR CHARACTERIZING MUTATIONS CAUSING BSS

Figure 4 presents an algorithm that can be used as a guide for the rational exploration of the molecular basis of BSS. Several features of this strategy will be discussed briefly here.


View larger version (30K):
[in this window]
[in a new window]
  		Fig 4. Algorithm for determining the genetic basis of BSS. Details are given in the text.

After a patient with the clinical characteristics of BSS has been identified, it is important to take as complete a medical history and family history as possible. Particularly important is a history of consanguinity in the parents. It is also vital to collect blood from as many of the relatives as possible, so as to be able to identify the affected gene and verify the mode of inheritance. Biochemical studies of the parents' platelets will also be useful in identifying the affected gene (discussed below).

The levels of the individual polypeptides on the patient's platelets should be determined by biochemical means to identify a candidate gene for sequencing. Quite often residual quantities of some of the polypeptides appear in the platelets of patients with a severe deficiency of one polypeptide. For example, in the GP IX mutants described by Wright et al,114 flow cytometry showed residual amounts of GP Ib in a subset of platelets, whereas GP IX was virtually undetectable; in BSS Kagoshima, due to truncation of GP Ibalpha , residual GP IX and GP Ibbeta were detected on the platelet surface.197 The polypeptide found to be most deficient by these assays will indicate which gene should be studied first by sequencing. Here too, studies of the parents' platelets may be useful. For example, in a patient severely deficient in all of the GP Ib-IX-V complex polypeptides whose parents are blood relatives, the finding of 2 bands for GP Ibalpha on immunoblots of platelets from 1 of the parents (indicating heterozygosity for the VNTR polymorphism) will rule out GP Ibalpha as the affected gene because the patient could not have inherited a defective GP Ibalpha allele from this parent. Similarly, if more than 1 patient in a family is affected, it is a relatively simple matter to rule out GP Ibalpha as the affected gene if any 1 of the affected individuals is heterozygous for the VNTR, or if any 2 are homozygous for different alleles. Homozygosity for this marker is not as informative; its predictive value is increased if the affected siblings are homozygous for all of the other GP Ibalpha polymorphisms, indicating that they inherited the same GP Ibalpha allele from both parents, an event with a probability of only 6.3% (for 2 siblings of heterozygous parents carrying the same mutant allele).

Several of the previously described mutations can be identified by restriction analysis of polymerase chain reaction (PCR)-amplified genomic DNA. One nonsense mutation of GP Ibalpha that produces a truncated polypeptide also ablates an Ava II site,198 a change that can be used as a marker for the presence or absence of the mutation. The C to T mutation that causes the Ala156right-arrowVal substitution responsible for the Bolzano variant of BSS introduces a new Hpa I site into the coding region of the GP Ibalpha gene,76 the Cys209right-arrowSer mutation produces a new Mse I site,199 and the Leu129right-arrowPro mutation eliminates a Sac I site.200 Both of the mutations of GP IX described by Wright et al114 (Asp21right-arrowGly and Asn45right-arrowSer) create new recognition sites for the enzyme Fnu4H1. Thus, several of the mutations known to be associated with BSS can be easily identified by restriction enzyme digestion of PCR-amplified DNA. If the restriction pattern indicates that the patient is heterozygous for 1 of the previously identified mutations, the other allele should be sequenced to identify the second mutation.

If this strategy fails to identify a candidate gene or no mutation is found in the suspected gene, the genes encoding all of the GP Ib-IX-V polypeptides can be sequenced. The relative simplicity of the gene structures makes direct sequencing the most straightforward approach for identifying mutations, particularly with the availability of automated sequencing. In addition, the paucity of intervening sequences obviates the need for reverse transcription of mRNAs, because the uninterrupted coding sequence can be obtained directly from genomic DNA (except in the GP Ibbeta gene, which has only 1 small intron interrupting the coding region). The order of priority shown (GP Ibalpha  > GP IX > GP Ibbeta  > GP V) is based on the relative frequency that the genes for the individual polypeptides have been found to be affected in reported cases of BSS. The GP V gene is given the lowest priority because it has not been reported as the affected gene causing BSS and because of the likelihood that the clinical sequelae of its absence will be less severe than those of the others. Failure to identify a mutation in any of the polypeptide coding regions suggests the possibility that the disorder is due to decreased transcription of 1 of the genes. The affected gene can be identified by the use of linkage markers to determine which of the genes is homozygous (in the offspring of a consanguineous union). The promoter regions of the gene identified by linkage markers can then be sequenced.

When an apparently homozygous mutation is identified in patients in whom the parents are not known to be consanguineous, it will be necessary to rule out a hemizygous situation in which the other allele has been deleted, rendering impossible its amplification by PCR. This is a particularly important concern with apparently homozygous mutations of the GP Ibbeta gene, because this gene usually undergoes hemizygous deletion in velo-cardio-facial syndrome,182 a condition whose manifestations can be subtle.201

Finally, when mutations are identified whose consequences are not obvious (eg, missense mutations), it is important that the causative nature of the mutation be demonstrated by expression and functional studies. Examples of some characterizations are given in the algorithm. Similarly, if a mutation is identified within 1 of the promoters that is believed to be responsible for decreased transcription, this should be determined by expression of the mutant promoter, perhaps directing the expression of a reporter gene in a megakaryocytic cell line.115,142,202

The molecular characterization of patients with platelet-type von Willebrand disease should focus on the N-terminus of GP Ibalpha , in particular in the disulfide loop between Cys209 and Cys248, where the previous mutations were identified.58,59,178,179

    CONCLUSIONS

BSS is a rare but fascinating disorder. Since its clinical description in 1948, analysis of its functional and molecular defects has spawned much of our current understanding of the role of the GP Ib-IX-V complex as a key receptor in initiating hemostasis. The continued analysis of the molecular and genetic defects in BSS should provide further information on the topography and assembly of the GP Ib-IX-V complex, on the role of this complex in the interactions of vWF and thrombin with platelets, on how its ligation activates platelets, on its role in coagulation, and on its participation in regulating platelet size and turnover.

    FOOTNOTES

   Submitted December 1, 1997; accepted March 3, 1998.
   Supported by grants from the National Institutes of Health, the American Heart Association, and the National Health and Research Council of Australia.
   Address reprint requests to José A. López, MD, Veterans Affairs Medical Center, Hematology/Oncology (111H), 2002 Holcombe Blvd, Houston, TX 77030; e-mail: josel{at}bcm.tmc.edu; or Michael C. Berndt, PhD, Baker Medical Research Institute, Commercial Road, Prahran, VIC 3181, Australia; e-mail: michael.berndt{at}baker.edu.au.

    ACKNOWLEDGMENT

It is a pleasure to acknowledge the assistance of David Smith with the preparation of this review.

    REFERENCES
Introduction
References

1. Bernard J, Soulier JP: Sur une nouvelle variété de dystrophie thrombocytaire-hémorragipare congénitale. Semin Hop Paris 24:3217, 1948

2. Gröttum KA, Solum NO: Congenital thrombocytopenia with giant platelets: A defect in the platelet membrane. Br J Haematol 16:277, 1969[Medline] [Order article via Infotrieve]

3. Howard MA, Hutton RA, Hardisty RM: Hereditary giant platelet syndrome: A disorder of a new aspect of platelet function. Br Med J 4:586, 1973

4. Caen JP, Levy-Toledano S: Interaction between platelets and von Willebrand factor provides a new scheme for primary haemostasis. Nature 244:159, 1973

5. Weiss HJ, Tschopp TB, Baumgartner HR, Sussman II, Johnson MM, Egan JJ: Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis. Am J Med 57:920, 1974[Medline] [Order article via Infotrieve]

6. Walsh PN, Mills DC, Pareti FI, Stewart GJ, Macfarlane DE, Johnson MM, Egan JJ: Hereditary giant platelet syndrome. Absence of collagen-induced coagulant activity and deficiency of factor-XI binding to platelets. Br J Haematol 29:639, 1975[Medline] [Order article via Infotrieve]

7. Perret B, Lévy-Toledano S, Plantavid M, Bredoux R, Chap H, Tobelem G, Douste-Blazy L, Caen JP: Abnormal phospholipid organization in Bernard-Soulier platelets. Thromb Res 31:529, 1983

8. Bevers EM, Comfurius P, Nieuwenhuis HK, Levy-Toledano S, Enouf J, Belluci S, Caen JP, Zwaal RF: Platelet prothrombin converting activity in hereditary disorders of platelet function. Br J Haematol 63:335, 1986[Medline] [Order article via Infotrieve]

9. Maldonado JE, Gilchrist GS, Brigden LP, Bowie EJ: Ultrastructure of platelets in Bernard-Soulier syndrome. Mayo Clinic Proc 50:402, 1975[Medline] [Order article via Infotrieve]

10. White JG: Inherited abnormalities of the platelet membrane and secretory granules. Hum Pathol 18:123, 1987[Medline] [Order article via Infotrieve]

11. Nurden AT, Caen JP: Specific roles for platelet surface glycoproteins in platelet function. Nature 255:720, 1975[Medline] [Order article via Infotrieve]

12. Clemetson KJ, McGregor JL, James E, Dechavanne M, Lüscher EF: Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high-resolution two-dimensional gel electrophoresis. J Clin Invest 70:304, 1982

13. Berndt MC, Gregory C, Chong BH, Zola H, Castaldi PA: Additional glycoprotein defects in Bernard-Soulier's syndrome: Confirmation of genetic basis by parental analysis. Blood 62:800, 1983[Abstract/Free Full Text]

14. Bernard J: History of congenital hemorrhagic thrombocytopathic dystrophy. Blood Cells 9:179, 1983[Medline] [Order article via Infotrieve]

15. Berndt MC, Fournier DJ, Castaldi PA: Bernard-Soulier syndrome. Clin Haematol 2:585, 1989

16. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL: Platelets and shear stress. Blood 88:1525, 1996[Free Full Text]

17. Du X, Beutler L, Ruan C, Castaldi PA, Berndt MC: Glycoprotein Ib and glycoprotein IX are fully complexed in the intact platelet membrane. Blood 69:1524, 1987[Abstract/Free Full Text]

18. Modderman PW, Admiraal LG, Sonnenberg A, von dem Borne AEGK: Glycoproteins V and Ib-IX form a noncovalent complex in the platelet membrane. J Biol Chem 267:364, 1992[Abstract/Free Full Text]

19. Michelson AD, Benoit SE, Furman MI, Barnard MR, Nurden P, Nurden AT: The platelet surface expression of glycoprotein V is regulated by two independent mechanisms: Proteolysis and the reversible cytoskeletal-mediated redistribution to the surface-connected canalicular system. Blood 87:1396, 1996[Abstract/Free Full Text]

20. Wu G, Essex DW, Meloni FJ, Takafuta T, Fujimura K, Konkle BA, Shapiro SS: Human endothelial cells in culture and in vivo express on their surface all four components of the glycoprotein Ib/IX/V complex. Blood 90:2660, 1997[Abstract/Free Full Text]

21. Kobe B, Deisenhofer J: The leucine-rich repeat: A versatile binding motif. Trends Biochem Sci 19:415, 1994[Medline] [Order article via Infotrieve]

22. López JA: The platelet glycoprotein Ib-IX complex. Blood Coagul Fibrinolysis 5:97, 1994[Medline] [Order article via Infotrieve]

23. Wenger RH, Wicki AN, Kieffer N, Adolph S, Hameister H, Clemetson KJ: The 5' flanking region and chromosomal localization of the gene encoding human platelet membrane glycoprotein Ibalpha . Gene 85:517, 1989[Medline] [Order article via Infotrieve]

24. Kelly MD, Essex DW, Shapiro SS, Meloni FJ, Druck T, Huebner K, Konkle BA: Complementary DNA cloning of the alternatively expressed endothelial cell glycoprotein Ibbeta (GPIbbeta ) and localization of the GPIbbeta gene to chromosome 22. J Clin Invest 93:2417, 1994

25. Yagi M, Edelhoff S, Disteche CM, Roth GJ: Structural characterization and chromosomal location of the gene encoding human platelet glycoprotein Ibbeta . J Biol Chem 269:17424, 1994[Abstract/Free Full Text]

26. Hickey MJ, Deaven LL, Roth GJ: Human platelet glycoprotein IX. Characterization of cDNA and localization of the gene to chromosome 3. FEBS Lett 274:189, 1990[Medline] [Order article via Infotrieve]

27. Yagi M, Edelhoff S, Disteche CM, Roth GJ: Human platelet glycoproteins V and IX: Mapping of two leucine-rich glycoprotein genes to chromosome 3 and analysis of structures. Biochemistry 34:16132, 1995[Medline] [Order article via Infotrieve]

28. Fox JE, Aggerbeck LP, Berndt MC: Structure of the glycoprotein Ib-IX complex from platelet membranes. J Biol Chem 263:4882, 1988[Abstract/Free Full Text]

29. Dong J-F, Li CQ, López JA: Tyrosine sulfation of the GP Ib-IX complex: Identification of sulfated residues and effect on ligand binding. Biochemistry 33:13946, 1994[Medline] [Order article via Infotrieve]

30. Ward CM, Andrews RK, Smith AI, Berndt MC: Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha . Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha -thrombin. Biochemistry 35:4929, 1996[Medline] [Order article via Infotrieve]

31. Lopez JA, Chung DW, Fujikawa K, Hagen FS, Papayannopoulou T, Roth GJ: Cloning of the alpha  chain of human platelet glycoprotein Ib: A transmembrane protein with homology to leucine-rich alpha 2-glycoprotein. Proc Natl Acad Sci USA 84:5615, 1987[Abstract/Free Full Text]

32. Kobe B, Deisenhofer J: Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats. Nature 366:751, 1993[Medline] [Order article via Infotrieve]

33. Judson PA, Anstee DJ, Clamp JR: Isolation and characterization of the major oligosaccharide of human platelet membrane glycoprotein GPIb. Biochem J 205:81, 1982[Medline] [Order article via Infotrieve]

34. Tsuji T, Tsunehisa S, Watanabe Y, Yamamoto K, Tohyama H, Osawa T: The carbohydrate moiety of human platelet glycocalicin. The structure of the major ser/thr-linked chain. J Biol Chem 258:6335, 1983[Abstract/Free Full Text]

35. Korrel SA, Clemetson KJ, Van Halbeek H, Kamerling JP, Sixma JJ, Vliegenthart JF: Structural studies on the O-linked carbohydrate chains of human platelet glycocalicin. Eur J Biochem 140:571, 1984[Medline] [Order article via Infotrieve]

36. López JA, Ludwig EH, McCarthy BJ: Polymorphism of human glycoprotein Ibalpha results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region. Structure/function implications. J Biol Chem 267:10055, 1992[Abstract/Free Full Text]

37. Ishida F, Furihata K, Ishida K, Yan J, Kitano K, Kiyosawa K, Furuta S: The largest variant of platelet glycoprotein Ibalpha has four tandem repeats of 13 amino acids in the macroglycopeptide region and a genetic linkage with methionine 145. Blood 86:1357, 1995[Abstract]

38. Lopez JA, Chung DW, Fujikawa K, Hagen FS, Davie EW, Roth GJ: The alpha  and beta  chains of human platelet glycoprotein Ib are both transmembrane proteins containing a leucine-rich amino acid sequence. Proc Natl Acad Sci USA 85:2135, 1988[Abstract/Free Full Text]

39. Wardell MR, Reynolds CC, Berndt MC, Wallace RW, Fox JE: Platelet glycoprotein Ibbeta is phosphorylated on serine 166 by cyclic AMP-dependent protein kinase. J Biol Chem 264:15656, 1989[Abstract/Free Full Text]

40. Fox JE, Berndt MC: Cyclic AMP-dependent phosphorylation of glycoprotein Ib inhibits collagen-induced polymerization of actin in platelets. J Biol Chem 264:9520, 1989[Abstract/Free Full Text]

41. Hickey MJ, Williams SA, Roth GJ: Human platelet glycoprotein IX: An adhesive prototype of leucine-rich glycoproteins with flank-center-flank structures. Proc Natl Acad Sci USA 86:6773, 1989[Abstract/Free Full Text]

42. Berndt MC, Gregory C, Kabral A, Zola H, Fournier D, Castaldi PA: Purification and preliminary characterization of the glycoprotein Ib complex in the human platelet membrane. Eur J Biochem 151:637, 1985[Medline] [Order article via Infotrieve]

43. Muszbek L, Laposata M: Glycoprotein Ib and glycoprotein IX in human platelets are acylated with palmitic acid through thioester linkages. J Biol Chem 264:9716, 1989[Abstract/Free Full Text]

44. Schick PK, Walker J: The acylation of megakaryocyte proteins: Glycoprotein IX is primarily myristoylated while glycoprotein Ib is palmitoylated. Blood 87:1377, 1996[Abstract/Free Full Text]

45. Lanza F, Morales M, de La Salle C, Cazenave J-P, Clemetson KJ, Shimomura T, Phillips DR: Cloning and characterization of the gene encoding the human platelet glycoprotein V. A member of the leucine-rich glycoprotein family cleaved during thrombin-induced platelet activation. J Biol Chem 268:20801, 1993[Abstract/Free Full Text]

46. Hickey MJ, Hagen FS, Yagi M, Roth GJ: Human platelet glycoprotein V: Characterization of the polypeptide and the related Ib-V-IX receptor system of adhesive, leucine-rich glycoproteins. Proc Natl Acad Sci USA 90:8327, 1993[Abstract/Free Full Text]

47. Li CQ, Dong J-F, Lanza F, Sanan DA, Sae-Tung G, López JA: Expression of platelet glycoprotein (GP) V in heterologous cells and evidence for its association with GP Ibalpha in forming a GP Ib-IX-V complex on the cell surface. J Biol Chem 270:16302, 1995[Abstract/Free Full Text]

48. Berndt MC, Phillips DR: Purification and preliminary physicochemical characterization of human platelet membrane glycoprotein V. J Biol Chem 256:59, 1981[Abstract/Free Full Text]

49. Springer TA: Adhesion receptors of the immune system. Nature 346:425, 1990[Medline] [Order article via Infotrieve]

50. Sixma JJ, Sakariassen KS, Stel HV, Houdijk WP, In der Maur DW, Hamer RJ, de Groot PG, van Mourik JA: Functional domains on von Willebrand factor. Recognition of discrete tryptic fragments by monoclonal antibodies that inhibit interaction of von Willebrand factor with platelets and with collagen. J Clin Invest 74:736, 1984

51. Fujimura Y, Titani K, Holland LZ, Russell SR, Roberts JR, Elder JH, Ruggeri ZM, Zimmerman TS: von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem 261:381, 1986[Abstract/Free Full Text]

52. Andrews RK, Gorman JJ, Booth WJ, Corino GL, Castaldi PA, Berndt MC: Cross-linking of a monomeric 39/34-kDa dispase fragment of von Willebrand factor (Leu-480/Val-481-Gly-718) to the N-terminal region of the alpha -chain of membrane glycoprotein Ib on intact platelets with bis(sulfosuccinimidyl) suberate. Biochemistry 28:8326, 1989[Medline] [Order article via Infotrieve]

53. Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh KA, Chopek MW, Sadler JE, Fujikawa K: Amino acid sequence of human von Willebrand factor. Biochemistry 25:3171, 1986[Medline] [Order article via Infotrieve]

54. Ruggeri ZM: von Willebrand factor. J Clin Invest 99:559, 1997[Medline] [Order article via Infotrieve]

55. Sakariassen KS, Bolhuis PA, Sixma JJ: Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to subendothelium. Nature 279:636, 1979[Medline] [Order article via Infotrieve]

56. Peterson DM, Stathopoulos NA, Giorgio TD, Hellums JD, Moake JL: Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. Blood 69:625, 1987[Abstract/Free Full Text]

57. Siediecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE: Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 88:2939, 1996[Abstract/Free Full Text]

58. Russell SD, Roth GJ: Pseudo-von Willebrand disease: A mutation in the platelet glycoprotein Ibalpha gene associated with a hyperactive surface receptor. Blood 81:1787, 1993[Abstract/Free Full Text]

59. Miller JL, Cunningham D, Lyle VA, Finch CN: Mutation in the gene encoding the alpha  chain of platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc Natl Acad Sci USA 88:4761, 1991[Abstract/Free Full Text]

60. Miller JL, Castella A: Platelet-type von Willebrand's disease: Characterization of a new bleeding disorder. Blood 60:790, 1982[Abstract/Free Full Text]

61. Weiss HJ, Meyer D, Rabinowitz R, Pietu G, Girma J-P, Vicic WJ, Rogers J: Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med 306:326, 1982[Abstract]

62. Ginsburg D, Sadler JE: Von Willebrand disease: A database of point mutations, insertions, and deletions. For the Consortium on von Willebrand Factor Mutations and Polymorphisms, and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 69:177, 1993[Medline] [Order article via Infotrieve]

63. Andrews RK, López JA, Berndt MC: Molecular mechanisms of platelet adhesion and activation. Int J Biochem Cell Biol 29:91, 1997[Medline] [Order article via Infotrieve]

64. Mohri H, Fujimura Y, Shima M, Yoshioka A, Houghten RA, Ruggeri ZM, Zimmerman T: Structure of the von Willebrand factor domain interacting with glycoprotein Ib. J Biol Chem 263:17901, 1988[Abstract/Free Full Text]

65. Girma JP, Takahashi Y, Yoshioka A, Diaz J, Meyer D: Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib. Thromb Haemost 64:326, 1990[Medline] [Order article via Infotrieve]

66. Berndt MC, Ward CM, Booth WJ, Castaldi PA, Mazurov AV, Andrews RK: Identification of aspartic acid 514 through glutamic acid 542 as a glycoprotein Ib-IX complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand factor by ristocetin and botrocetin. Biochemistry 31:11144, 1992[Medline] [Order article via Infotrieve]

67. Sugimoto M, Mohri H, McClintock RA, Ruggeri ZM: Identification of discontinuous von Willebrand factor sequences involved in complex formation with botrocetin. A model for the regulation of von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem 266:18172, 1991[Abstract/Free Full Text]

68. Matsushita T, Sadler JE: Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor. J Biol Chem 270:13406, 1995[Abstract/Free Full Text]

69. Vicente V, Kostel PJ, Ruggeri ZM: Isolation and functional characterization of the von Willebrand factor-binding domain located between residues His1-Arg293 of the alpha -chain of glycoprotein Ib. J Biol Chem 263:18473, 1988[Abstract/Free Full Text]

70. Andrews RK, Booth WJ, Gorman JJ, Castaldi PA, Berndt MC: Purification of botrocetin from Bothrops jararaca venom. Analysis of the botrocetin-mediated interaction between von Willebrand factor and the human platelet membrane glycoprotein Ib-IX complex. Biochemistry 28:8317, 1989[Medline] [Order article via Infotrieve]

71. Murata M, Ware J, Ruggeri ZM: Site-directed mutagenesis of a soluble recombinant fragment of platelet glycoprotein Ibalpha demonstrating negatively charged residues involved in von Willebrand factor binding. J Biol Chem 266:15474, 1991[Abstract/Free Full Text]

72. Marchese P, Murata M, Mazzucato M, Pradella P, De Marco L, Ware J, Ruggeri ZM: Identification of three tyrosine residues of glycoprotein Ibalpha with distinct roles in von Willebrand factor and alpha -thrombin binding. J Biol Chem 270:9571, 1995[Abstract/Free Full Text]

73. Cruz MA, Petersen E, Turci SM, Handin RI: Functional analysis of a recombinant glycoprotein Ibalpha polypeptide which inhibits von Willebrand factor binding to the platelet glycoprotein Ib-IX complex and to collagen. J Biol Chem 267:1303, 1992[Abstract/Free Full Text]

74. Hess D, Schaller J, Rickli EE, Clemetson KJ: Identification of the disulphide bonds in human platelet glycocalicin. Eur J Biochem 199:389, 1991[Medline] [Order article via Infotrieve]

75. Miller JL, Lyle VA, Cunningham D: Mutation of leucine-57 to phenylalanine in a platelet glycoprotein Ibalpha leucine tandem repeat occurring in patients with an autosomal dominant variant of Bernard-Soulier disease. Blood 79:439, 1992[Abstract/Free Full Text]

76. Ware J, Russell SR, Marchese P, Murata M, Mazzucato M, De Marco L, Ruggeri ZM: Point mutation in a leucine-rich repeat of platelet glycoprotein Ibalpha resulting in the Bernard-Soulier syndrome. J Clin Invest 92:1213, 1993

77. Savage B, Saldivar E, Ruggeri ZM: Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 84:289, 1996[Medline] [Order article via Infotrieve]

78. Moroi M, Jung SM, Nomura S, Sekiguchi S, Ordinas A, Diaz-Ricart M: Analysis of the involvement of the von Willebrand factor-glycoprotein Ib interaction in platelet adhesion to a collagen-coated surface under flow conditions. Blood 90:4413, 1997[Abstract/Free Full Text]

79. De Marco L, Mazzucato M, Masotti A, Ruggeri ZM: Localization and characterization of an alpha -thrombin-binding site on platelet glycoprotein Ibalpha . J Biol Chem 269:6478, 1994[Abstract/Free Full Text]

80. Katagiri Y, Hayashi Y, Yamamoto K, Tanoue K, Kosaki G, Yamazaki H: Localization of von Willebrand factor and thrombin-interactive domains on human platelet glycoprotein Ib. Thromb Haemost 63:122, 1990[Medline] [Order article via Infotrieve]

81. Gralnick HR, Williams S, McKeown LP, Hansmann K, Fenton JW, Krutzsch H: High-affinity alpha -thrombin binding to platelet glycoprotein Ibalpha : Identification of two binding domains. Proc Natl Acad Sci USA 91:6334, 1994[Abstract/Free Full Text]

82. Dong J-F, Sae-Tung G, López JA: Role of glycoprotein V in the formation of the platelet high affinity thrombin-binding site. Blood 89:4355, 1997[Abstract/Free Full Text]

83. Vu TH, Hung DT, Wheaton VI, Coughlin SR: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64:1057, 1991[Medline] [Order article via Infotrieve]

84. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR: Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386:502, 1997[Medline] [Order article via Infotrieve]

85. Jamieson GA, Okumura T: Reduced thrombin binding and aggregation in Bernard-Soulier platelets. J Clin Invest 61:861, 1978

86. Berndt MC, Gregory C, Dowden G, Castaldi PA: Thrombin interactions with platelet membrane proteins. Ann NY Acad Sci 485:374, 1986[Medline] [Order article via Infotrieve]

87. Greco NJ, Tandon NN, Jones GD, Kornhauser R, Jackson B, Yamamoto N, Tanoue K, Jamieson GA: Contribution of glycoprotein Ib and the seven transmembrane domain receptor to increases in platelet cytoplasmic [Ca2+] induced by alpha -thrombin. Biochemistry 35:906, 1996[Medline] [Order article via Infotrieve]

88. Jamieson GA: Pathophysiology of platelet thrombin receptors. Thromb Haemost 78:242, 1997[Medline] [Order article via Infotrieve]

89. Shattil SJ, Ginsberg MH, Brugge JS: Adhesive signaling in platelets. Curr Opin Cell Biol 6:695, 1994[Medline] [Order article via Infotrieve]

90. Du X, Ginsberg MH: Integrin alpha IIbbeta 3 and platelet function. Thromb Haemost 78:96, 1997[Medline] [Order article via Infotrieve]

91. Andrews RK, Kroll MH, Ward CM, Rose JW, Scarborough RM, Smith AI, López JA, Berndt MC: Binding of a novel 50-kDa alboaggregin from Trimeresurus albolabris and related viper venom proteins to the platelet membrane glycoprotein Ib-IX-V complex. Effect on platelet aggregation and glycoprotein Ib-mediated platelet activation. Biochemistry 35:12629, 1996[Medline] [Order article via Infotrieve]

92. Kroll MH, Harris TS, Moake JL, Handin RI, Schafer AI: von Willebrand factor binding to platelet GpIb initiates signals for platelet activation. J Clin Invest 88:1568, 1991

93. Ikeda Y, Handa M, Kamata T, Kawano K, Kawai Y, Watanabe K, Kawakami K, Sakai K, Fukuyama M, Itagaki I, Yoshioka A, Ruggeri ZM: Transmembrane calcium influx associated with von Willebrand factor binding to GP Ib in the initiation of shear-induced platelet aggregation. Thromb Haemost 69:496, 1993[Medline] [Order article via Infotrieve]

94. Jackson SP, Schoenwaelder SM, Yuan Y, Rabinowitz I, Salem HH, Mitchell CA: Adhesion receptor activation of phosphatidylinositol 3-kinase. von Willebrand factor stimulates the cytoskeletal association and activation of phosphatidylinositol 3-kinase and pp60c-src in human platelets. J Biol Chem 269:27093, 1994[Abstract/Free Full Text]

95. Razdan K, Hellums JD, Kroll MH: Shear-stress-induced von Willebrand factor binding to platelets causes the activation of tyrosine kinase(s). Biochem J 302:681, 1994

96. Andrews RK, Fox JE: Identification of a region in the cytoplasmic domain of the platelet membrane glycoprotein Ib-IX complex that binds to purified actin-binding protein. J Biol Chem 267:18605, 1992[Abstract/Free Full Text]

97. Fox JE, Boyles JK, Berndt MC, Steffen PK, Anderson LK: Identification of a membrane skeleton in platelets. J Cell Biol 106:1525, 1988[Abstract/Free Full Text]

98. Hartwig JH, DeSisto M: The cytoskeleton of the resting human blood platelet: Structure of the membrane skeleton and its attachment to actin filaments. J Cell Biol 112:407, 1991[Abstract/Free Full Text]

99. Fox JEB, Lipfer L, Clark EA, Reynolds CC, Austin CD, Brugge JS: On the role of the platelet membrane skeleton in mediating signal transduction. J Biol Chem 268:25973, 1993[Abstract/Free Full Text]

100. (suppl 4) Fox JE: Platelet activation: New aspects. Haemostasis 26:102, 1996

101. Fox JE: The platelet cytoskeleton. Thromb Haemost 70:884, 1993[Medline] [Order article via Infotrieve]

102. Dong J-F, Li CQ, Sae-Tung G, Hyun W, Afshar-Kharghan V, López JA: The cytoplasmic domain of glycoprotein(GP) Ibalpha constrains the lateral diffusion of the GP Ib-IX complex and modulates von Willebrand factor binding. Biochemistry 36:12421, 1997[Medline] [Order article via Infotrieve]

103. Du X, Harris SJ, Tetaz TJ, Ginsberg MH, Berndt MC: Association of a phospholipase A2 (14-3-3 protein) with the platelet glycoprotein Ib-IX complex. J Biol Chem 269:18287, 1994[Abstract/Free Full Text]

104. Du X, Fox JE, Pei S: Identification of a binding sequence for the 14-3-3 protein within the cytoplasmic domain of the adhesion receptor, platelet glycoprotein Ibalpha . J Biol Chem 271:7362, 1996[Abstract/Free Full Text]

105. Zupan LA, Steffens DL, Berry CA, Landt M, Gross RW: Cloning and expression of a human 14-3-3 protein mediating phospholipolysis. Identification of an arachidonoyl-enzyme intermediate during catalysis. J Biol Chem 267:8707, 1992[Abstract/Free Full Text]

106. Robinson K, Jones D, Patel Y, Martin H, Madrazo J, Martin S, Howell S, Elmore M, Finnen MJ, Aitken A: Mechanism of inhibition of protein kinase C by 14-3-3 isoforms. 14-3-3 isoforms do not have phospholipase A2 activity. Biochem J 299:853, 1994

107. Aitken A: 14-3-3 and its possible role in co-ordinating multiple signalling pathways. Trends Cell Biol 6:341, 1996 [Medline] [Order article via Infotrieve]

108. Muslin AJ, Tanner JW, Allen PM, Shaw AS: Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84:889, 1996[Medline] [Order article via Infotrieve]

109. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87:619, 1996[Medline] [Order article via Infotrieve]

110. Andrews RK, Harris SJ, McNally T, Berndt MC: Binding of purified 14-3-3zeta signaling protein to discrete amino acid sequences within the cytoplasmic domain of the platelet membrane glycoprotein Ib-IX-V complex. Biochemistry 37:638, 1998[Medline] [Order article via Infotrieve]

111. López JA, Leung B, Reynolds CC, Li CQ, Fox JE: Efficient plasma membrane expression of a functional platelet glycoprotein Ib-IX complex requires the presence of its three subunits. J Biol Chem 267:12851, 1992[Abstract/Free Full Text]

112. López JA, Weisman S, Sanan DA, Sih T, Chambers M, Li CQ: Glycoprotein (GP) Ibbeta is the critical subunit linking GP Ibalpha and GP IX in the GP Ib-IX complex. Analysis of partial complexes. J Biol Chem 269:23716, 1994[Abstract/Free Full Text]

113. López JA, Li CQ, Weisman S, Chambers M: The GP Ib-IX "complex-specific" monoclonal antibody SZ1 binds to a conformation-sensitive epitope on GP IX: Implications for the target antigen of quinine/quinidine-dependent autoantibodies. Blood 85:1254, 1995[Abstract/Free Full Text]

114. Wright SD, Michaelides K, Johnson DJ, West NC, Tuddenham EG: Double heterozygosity for mutations in the platelet glycoprotein IX gene in three siblings with Bernard-Soulier syndrome. Blood 81:2339, 1993[Abstract/Free Full Text]

115. Ludlow LB, Schick BP, Budarf ML, Driscoll DA, Zackai EH, Cohen A, Konkle BA: Identification of a mutation in a GATA binding site of the platelet glycoprotein Ibbeta promoter resulting in the Bernard-Soulier syndrome. J Biol Chem 271:22076, 1996[Abstract/Free Full Text]

116. Noda M, Fujimura K, Takafuta T, Shimomura T, Fujimoto T, Yamamoto N, Tanoue K, Arai M, Suehiro A, Kakishita E, Shimasaki A, Kuramoto A: Heterogenous expression of glycoprotein Ib, IX and V in platelets from two patients with Bernard-Soulier syndrome caused by different genetic abnormalities. Thromb Haemost 74:1411, 1995[Medline] [Order article via Infotrieve]

117. Meyer S, Kresbach G, Häring P, Schumpp-Vonach B, Clemetson KJ, Hadváry P, Steiner B: Expression and characterization of functionally active fragments of the platelet glycoprotein (GP) Ib-IX complex in mammalian cells. Incorporation of GP Ibalpha into the cell surface membrane. J Biol Chem 268:20555, 1993[Abstract/Free Full Text]

118. Calverley DC, Yagi M, Stray SM, Roth GJ: Human platelet glycoprotein V: Its role in enhancing expression of the glycoprotein Ib receptor. Blood 86:1361, 1995[Abstract/Free Full Text]

119. Meyer SC, Fox JE: Interaction of platelet glycoprotein V with glycoprotein Ib-IX regulates expression of the glycoprotein and binding of von Willebrand factor to glycoprotein Ib-IX in transfected cells. J Biol Chem 270:14693, 1995[Abstract/Free Full Text]

120. Afshar-Kharghan V, López JA: Bernard-Soulier syndrome caused by a dinucleotide deletion and reading frameshift in the region encoding the glycoprotein Ibalpha transmembrane domain. Blood 90:2634, 1997[Abstract/Free Full Text]

121. Noda M, Fujimura K, Takafuta T, Shimomura T, Fujii T, Katsutani S, Fujimoto T, Kuramoto A, Yamazaki T, Mochizuki T, Matsuzaki M, Sano M: A point mutation in glycoprotein IX coding sequence (Cys73(TGT) to Tyr(TAT)) causes impaired surface expression of GP Ib-IX-V complex in two families with Bernard-Soulier syndrome. Thromb Haemost 6:874, 1996

122. Holmberg L, Karpman D, Nilsson I, Olofsson T: Bernard-Soulier syndrome Karlstad: Trp 498right-arrowStop mutation resulting in a truncated glycoprotein Ibalpha that contains part of the transmembrane domain. Br J Haematol 98:57, 1997[Medline] [Order article via Infotrieve]

123. Wu G, Meloni FJ, Shapiro SS: Platelet glycoprotein (Gp) IX associates with Gp Ibalpha in the platelet membrane GpIb complex. Blood 87:2782, 1996[Abstract/Free Full Text]

124. (abstr, suppl 1) Dong J-F, López JA: Complex formation and intracellular transport of the polypeptides of the platelet glycoprotein Ib-IX-V complex. Blood 88:624a, 1996

125. Wenger RH, Kieffer N, Wicki AN, Clemetson KJ: Structure of the human blood platelet membrane glycoprotein Ibalpha gene. Biochem Biophys Res Commun 156:389, 1988[Medline] [Order article via Infotrieve]

126. Hickey MJ, Roth GJ: Characterization of the gene encoding human platelet glycoprotein IX. J Biol Chem 268:3438, 1993[Abstract/Free Full Text]

127. Mikol DD, Alexakos MJ, Bayley CA, Lemons RS, Le Beau MM, Stefansson K: Structure and chromosomal localization of the gene for the oligodendrocyte-myelin glycoprotein. J Cell Biol 111:2673, 1990[Abstract/Free Full Text]

128. Sprandio JD, Shapiro SS, Thiagarajan P, McCord S: Cultured human umbilical vein endothelial cells contain a membrane glycoprotein immunologically related to platelet glycoprotein Ib. Blood 71:234, 1988[Abstract/Free Full Text]

129. Asch AS, Adelman B, Fujimoto M, Nachman RL: Identification and isolation of a platelet GPIb-like protein in human umbilical vein endothelial cells and bovine aortic smooth muscle cells. J Clin Invest 81:1600, 1988

130. Konkle BA, Shapiro SS, Asch AS, Nachman RL: Cytokine-enhanced expression of glycoprotein Ibalpha in human endothelium. J Biol Chem 265:19833, 1990[Abstract/Free Full Text]

131. Rajagopalan V, Essex DW, Shapiro SS, Konkle BA: Tumor necrosis factor-alpha modulation of glycoprotein Ibalpha expression in human endothelial and erythroleukemia cells. Blood 80:153, 1992[Abstract/Free Full Text]

132. Zieger B, Hashimoto Y, Ware J: Alternative expression of platelet glycoprotein Ibbeta mRNA from an adjacent 5' gene with an imperfect polyadenylation signal sequence. J Clin Invest 99:520, 1997[Medline] [Order article via Infotrieve]

133. Beacham DA, Cruz MA, Handin RI: Glycoprotein Ib can mediate endothelial cell attachment to a von Willebrand factor substratum. Thromb Haemost 73:309, 1995[Medline] [Order article via Infotrieve]

134. Bombeli T, Schwartz BR, Harlan JM: Adhesion of activated platelets to endothelial cells: Evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alpha vbeta 3 integrin, and GPIbalpha . J Exp Med 187:329, 1998[Abstract/Free Full Text]

135. Perrault C, Lankhof H, Pidard D, Kerbiriou-Nabias D, Sixma JJ, Meyer D, Baruch D: Relative importance of the glycoprotein Ib-binding domain and the RGD sequence of von Willebrand factor for its interaction with endothelial cells. Blood 90:2335, 1997[Abstract/Free Full Text]

136. Uzan G, Prenant M, Prandini M-H, Martin F, Marguerie G: Tissue-specific expression of the platelet GPIIb gene. J Biol Chem 266:8932, 1991[Abstract/Free Full Text]

137. Prandini M-H, Uzan G, Martin F, Thevenon D, Marguerie G: Characterization of a specific erythromegakaryocytic enhancer within the glycoprotein IIb promoter. J Biol Chem 267:10370, 1992[Abstract/Free Full Text]

138. Lemarchandel V, Ghysdael J, Mignotte V, Rahuel C, Roméo P-H: GATA and Ets cis-acting sequences mediate megakaryocyte-specific expression. Mol Cell Biol 13:668, 1993[Abstract/Free Full Text]

139. Martin F, Prandini M-H, Thevenon D, Marguerie G, Uzan G: The transcription factor GATA-1 regulates the promoter activity of the platelet glycoprotein IIb gene. J Biol Chem 268:21606, 1993[Abstract/Free Full Text]

140. Block KL, Poncz M: Platelet glycoprotein IIb gene expression as a model of megakaryocyte-specific expression. Stem Cells 13:135, 1995[Medline] [Order article via Infotrieve]

141. Hashimoto Y, Ware J: Identification of essential GATA and Ets binding motifs within the promoter of the platelet glycoprotein Ibalpha gene. J Biol Chem 270:24532, 1995[Abstract/Free Full Text]

142. Bastian LS, Yagi M, Chan C, Roth GJ: Analysis of the megakaryocyte glycoprotein IX promoter identifies positive and negative regulatory domains and functional GATA and Ets sites. J Biol Chem 271:18554, 1996[Abstract/Free Full Text]

143. Tsang AP, Visvader JE, Turner CA, Fujiwara Y, Yu C, Weiss MJ, Crossley M, Orkin SH: FOG, a multiple zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell 90:109, 1997[Medline] [Order article via Infotrieve]

144. Krause DS, Perkins AS: Gotta find GATA a friend. Nat Med 3:960, 1997[Medline] [Order article via Infotrieve]

145. Moroi M, Jung SM, Yoshida N: Genetic polymorphism of platelet glycoprotein Ib. Blood 64:622, 1984[Abstract/Free Full Text]

146. Meyer M, Schellenberg I: Platelet membrane glycoprotein Ib: Genetic polymorphism detected in the intact molecule and in proteolytic fragments. Thromb Res 58:233, 1990[Medline] [Order article via Infotrieve]

147. Murata M, Furihata K, Ishida F, Russell SR, Ware J, Ruggeri ZM: Genetic and structural characterization of an amino acid dimorphism in glycoprotein Ibalpha involved in platelet transfusion refractoriness. Blood 79:3086, 1992[Abstract/Free Full Text]

148. Kuijpers RW, Faber NM, Cuypers HT, Ouwehand WH, von dem Borne AE: NH2-terminal globular domain of human platelet glycoprotein Ibalpha has a methionine145/threonine145 amino acid polymorphism, which is associated with the HPA-2 (Ko) alloantigens. J Clin Invest 89:381, 1992

149. Simsek S, Bleeker PM, van der Schoot CE, von dem Borne AE: Association of variable number of tandem repeats (VNTR) in glycoprotein Ibalpha and HPA-2 alloantigens. Thromb Haemost 72:757, 1994[Medline] [Order article via Infotrieve]

150. Ishida F, Saji H, Maruya E, Furihata K: Human platelet-specific antigen, Siba, is associated with the molecular weight polymorphism of glycoprotein Ibalpha . Blood 78:1722, 1991[Abstract/Free Full Text]

151. Kaski S, Kekomaki R, Partanen J: Systematic screening for genetic polymorphism in human platelet glycoprotein Ibalpha . Immunogenetics 44:170, 1996[Medline] [Order article via Infotrieve]

152. Suzuki K, Hayashi T, Akiba J, Yahagi A, Tajima K, Satoh S, Sasaki H: Sty I polymorphism at nucleotide 1610 in the human platelet glycoprotein Ib alpha gene. Jpn J Human Genet 41:419, 1996

153. Lindsay EA, Shaffer LG, Carrozzo R, Greenberg F, Baldini A: De novo tandem duplication of chromosome segment 22q11-q12: Clinical, cytogenetic, and molecular characterization. Am J Med Genet 56:296, 1995[Medline] [Order article via Infotrieve]

154. Buetow KH, Duggan D, Yang B, Ludwigsen S, Puck J, Porter J, Budarf M, Spielman R, Emanuel BS: A microsatellite-based multipoint index map of human chromosome 22. Genomics 18:329, 1993[Medline] [Order article via Infotrieve]

155. Fibison WJ, Budarf M, McDermid H, Greenberg F, Emanuel BS: Molecular studies of DiGeorge syndrome. Am J Hum Genet 46:888, 1990[Medline] [Order article via Infotrieve]

156. MacCollin M, Romano D, Budarf M, Denny C, Trofatter J, Menon A, Rouleau G, Fontaine B, Emanuel B, Gusella J: A set of STS assays targeting the chromosome 22 physical framework markers. Genomics 15:680, 1993[Medline] [Order article via Infotrieve]

157. Berndt MC: Congenital disorders of platelet function , in Loscalzo J, Schafer AI (eds): Thrombosis and Hemorrhage. Boston, MA, Blackwell Scientific , 1994 , p 615

158. Grové SS, Kromberg JGR: Bernard-Soulier syndrome in two Afrikaner families. S Afr Med J 67:1050, 1985[Medline] [Order article via Infotrieve]

159. Mant MJ: DDAVP in Bernard-Soulier syndrome. Thromb Res 52:77, 1988[Medline] [Order article via Infotrieve]

160. Caen JP, Nurden AT, Jeanneau C, Michel H, Tobelem G, Levy-Toledano S, Sultan Y, Valensi F, Bernard J: Bernard-Soulier syndrome: A new platelet glycoprotein abnormality. Its relationship with platelet adhesion to subendothelium and with the factor VIII von Willebrand protein. J Lab Clin Med 87:586, 1976[Medline] [Order article via Infotrieve]

161. Peaceman AM, Katz AR, Laville M: Bernard-Soulier syndrome complicating pregnancy: A case report. Obstet Gynecol 73:457, 1989[Medline] [Order article via Infotrieve]

162. Michalas S, Malamitsi-Puchner A, Tsevrenis H: Pregnancy and delivery in Bernard-Soulier syndrome. Acta Obstet Gynecol Scand 63:185, 1984[Medline] [Order article via Infotrieve]

163. Heslop HE, Hickton CM, Laird E, Tait JD, Doig JR, Beard EJ: Twin pregnancy and parturition in a patient with the Bernard Soulier syndrome. Scand J Haematol 37:71, 1986[Medline] [Order article via Infotrieve]

164. Saade G, Homsi R, Seoud M: Bernard-Soulier syndrome in pregnancy; a report of four pregnancies in one patient, and review of the literature. Eur J Obstet Gynecol Reprod Biol 40:149, 1991[Medline] [Order article via Infotrieve]

165. Peng TC, Kickler TS, Bell WR, Haller E: Obstetric complications in a patient with Bernard-Soulier syndrome. Am J Obstet Gynecol 165:425, 1991[Medline] [Order article via Infotrieve]

166. Avila MA, Jacyntho C, Santos ML, Murta C, Hoirich S, Chalon I, Resende O: Syndrome de Bernard-Soulier et grossesse: Un cas. J Gynecol Obstet Biol Reprod 21:73, 1992[Medline] [Order article via Infotrieve]

167. de Moerloose P, Vogel JJ, Clemetson KJ, Petite J, Bienz D, Bouvier CA: Syndrome de Bernard-Soulier dans une famille suisse. Schweiz Med Wochenschr 117:1817, 1987[Medline] [Order article via Infotrieve]

168. Cuthbert RJG, Watson HHK, Handa SI, Abbott I, Ludlam CA: DDAVP shortens the bleeding time in Bernard-Soulier syndrome. Thromb Res 49:649, 1988[Medline] [Order article via Infotrieve]

169. Bunescu A, Lindahl T, Solum NO, Schulman S, Larsson A, Lundahl J, Egberg N: Partial expression of GPIb measured by flow cytometry in two patients with Bernard-Soulier syndrome. Thromb Res 76:441, 1994[Medline] [Order article via Infotrieve]

170. Li C, Pasquale DN, Roth GJ: Bernard-Soulier syndrome with severe bleeding: Absent platelet glycoprotein Ib alpha due to a homozygous one-base deletion. Thromb Haemost 76:670, 1996[Medline] [Order article via Infotrieve]

171. Waldenström E, Holmberg L, Axelsson U, Winqvist I, Nilsson IM: Bernard-Soulier syndrome in two Swedish families: Effect of DDAVP on bleeding time. Eur J Haematol 46:182, 1991[Medline] [Order article via Infotrieve]

172. Simsek S, Admiraal LG, Modderman PW, van der Schoot CE, von dem Borne AEGK: Identification of a homozygous single base pair deletion in the gene coding for the human platelet glycoprotein Ibalpha causing Bernard-Soulier syndrome. Thromb Haemost 72:444, 1994[Medline] [Order article via Infotrieve]

173. Nomura K, Harioka T, Itoh T, Kitajima T, Uno K, Kagawa D, Sone T: Anesthetic management of a patient with Bernard-Soulier syndrome. Masui 42:1521, 1993[Medline] [Order article via Infotrieve]

174. Kemahli S, Canatan D, Uysal Z, Akar N, Cin S, Arcasoy A: DDAVP shortens bleeding time in Bernard-Soulier syndrome. Thromb Haemost 71:675, 1994[Medline] [Order article via Infotrieve]

175. De Marco L, Mazzucato M, Fabris F, De Roia D, Coser P, Girolami A, Vicente V, Ruggeri ZM: Variant Bernard-Soulier syndrome type Bolzano. A congenital bleeding disorder due to a structural and functional abnormality of the platelet glycoprotein Ib-IX complex. J Clin Invest 86:25, 1990

176. Kenny D, Newman PJ, Morateck PA, Montgomery RR: A dinucleotide deletion results in defective membrane anchoring and circulating soluble glycoprotein Ibalpha in a novel form of Bernard-Soulier syndrome. Blood 90:2626, 1997[Abstract/Free Full Text]

177. (abstr) Kaski S, Partanen J, Salmi TT, Kekomäki R: Different molecular origin of Bernard-Soulier syndrome (BSS) reflected in varying expression of platelet glycoprotein (GP) Ib/IX/V complex. Thromb Haemost 77:68, 1997

178. Takahashi H, Murata M, Moriki T, Anbo H, Furukawa T, Nikkuni K, Shibata A, Handa M, Kawai Y, Watanabe K, Ikeda Y: Substitution of Val for Met at residue 239 of platelet glycoprotein Ibalpha in Japanese patients with platelet-type von Willebrand disease. Blood 85:727, 1995[Abstract/Free Full Text]

179. Kunishima S, Heaton DC, Naoe T, Hickton C, Mizuno S, Saito H, Kamiya T: De novo mutation of the platelet glycoprotein Ibalpha gene in a patient with pseudo-von Willebrand disease. Blood Coagul Fibrinolysis 8:311, 1997[Medline] [Order article via Infotrieve]

180. Pincus MR, Dykes DC, Carty RP, Miller JL: Conformational energy analysis of the substitution of Val for Gly 233 in a functional region of platelet GPIbalpha in platelet-type von Willebrand disease. Biochim Biophys Acta 1097:133, 1991[Medline] [Order article via Infotrieve]

181. Pincus MR, Carty RP, Miller JL: Structural implications of the substitution of Val for Met at residue 239 in the alpha chain of human platelet glycoprotein IB. J Prot Chem 13:629, 1994[Medline] [Order article via Infotrieve]

182. Budarf ML, Konkle BA, Ludlow LB, Michaud D, Li M, Yamashiro DJ, McDonald D, Zackai EH, Driscoll DA: Identification of a patient with Bernard-Soulier syndrome and a deletion in the DiGeorge/Velo-cardio-facial chromosomal region in 22q11.2. Hum Mol Genet 4:763, 1995[Free Full Text]

183. Kunishima S, Lopez JA, Kobayashi S, Imai N, Kamiya T, Saito H, Naoe T: Missense mutations of the glycoprotein (GP) Ibbeta gene impairing the GPIb alpha /beta disulfide linkage in a family with giant platelet disorder. Blood 89:2404, 1997[Abstract/Free Full Text]

184. Sae-Tung G, Dong J, López JA: Biosynthetic defect in platelet glycoprotein IX mutants associated with Bernard-Soulier syndrome. Blood 87:1361, 1996[Abstract/Free Full Text]

185. Berndt MC, Kabral A, Grimsley P, Watson N, Robertson TI, Bradstock KF: An acquired Bernard-Soulier-like platelet defect associated with juvenile myelodysplastic syndrome. Br J Haematol 68:97, 1988[Medline] [Order article via Infotrieve]

186. Hiçsönmez G, Gümrük F, Çetin M, Özbek N, Tüncer M, Gürsel T: Bernard-Soulier-like functional platelet defect in myelodysplastic syndrome and in acute myeloblastic leukemia associated with trilineage myelodysplasia. Turk J Pediatr 37:425, 1995[Medline] [Order article via Infotrieve]

187. Devine DV, Currie MS, Rosse WF, Greenberg CS: Pseudo-Bernard-Soulier syndrome: Thrombocytopenia caused by autoantibody to platelet glycoprotein Ib. Blood 70:428, 1987[Abstract/Free Full Text]

188. Varon D, Gitel SN, Varon N, Lahav J, Dardik R, Klepfish A, Berrebi A: Immune Bernard Soulier-like syndrome associated with anti-glycoprotein-IX antibody. Am J Hematol 41:67, 1992[Medline] [Order article via Infotrieve]

189. Beales ILP: An acquired-pseudo Bernard Soulier syndrome occuring with autoimmune chronic active hepatitis and anti-cardiolipin antibody. Postgrad Med J 70:305, 1994[Abstract/Free Full Text]

190. White JG, Burris SM, Hasegawa D, Johnson M: Micropipette aspiration of human blood platelets: A defect in Bernard-Soulier's syndrome. Blood 63:1249, 1984[Abstract/Free Full Text]

191. McNicol A, Drouin J, Clemetson KJ, Gerrard JM: Phospholipase C activity in platelets from Bernard-Soulier syndrome patients. Arterioscler Thromb 13:1567, 1993[Abstract/Free Full Text]

192. Caen JP, Bellucci S: The defective prothrombin consumption in Bernard-Soulier syndrome. Hypotheses from 1948 to 1982. Blood Cells 9:389, 1983[Medline] [Order article via Infotrieve]

193. Bockenstedt PL: Laboratory methods in hemostasis , in Loscalzo J, Schafer AI (eds): Thrombosis and Hemorrhage. Boston, MA, Blackwell Scientific , 1994 , p 455

194. Bradford HN, Dela Cadena RA, Kunapuli SP, Dong J-F, López JA, Colman RW: Human kininogens regulate thrombin binding to platelets through the glycoprotein Ib-IX-V complex. Blood 90:1508, 1997[Abstract/Free Full Text]

195. (abstr) Joseph K, Bahou W, Kaplan AP: Evidence that the zinc-dependent platelet-binding protein of factor XII and high molecular weight kininogen is glycoprotein Ib. J Invest Med 45:267A, 1997

196. Coller BS, Peerschke EI, Lesley E, Scudder LE, Sullivan CA: Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: Additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood 61:99, 1983[Abstract/Free Full Text]

197. Kunishima S, Miura H, Fukutani H, Yoshida H, Osumi K, Kobayashi S, Ohno R, Naoe T: Bernard-Soulier syndrome Kagoshima: Ser 444 right-arrow Stop mutation of glycoprotein (GP) Ibalpha resulting in circulating truncated GPIbalpha and surface expression of GPIbbeta and GPIX. Blood 84:3356, 1994[Abstract/Free Full Text]

198. Ware J, Russell SR, Vicente V, Scharf RE, Tomer A, McMillan R, Ruggeri ZM: Nonsense mutation in the glycoprotein Ibalpha coding sequence associated with Bernard-Soulier syndrome. Proc Natl Acad Sci USA 87:2026, 1990[Abstract/Free Full Text]

199. Simsek S, Noris P, Lozano M, Pico M, von dem Borne AEGK, Ribera A, Gallardo D: Cys209Ser mutation in the platelet membrane glycoprotein Ibalpha gene is associated with Bernard Soulier syndrome. Br J Haematol 88:839, 1994[Medline] [Order article via Infotrieve]

200. Li C, Martin S, Roth G: The genetic defect in two well-studied cases of Bernard-Soulier syndrome: A point mutation in the fifth leucine-rich repeat of platelet glycoprotein Ibalpha . Blood 86:3805, 1996[Abstract/Free Full Text]

201. Lipson AH, Yuille D, Angel M, Thompson PG, Vandervoord JG, Beckenham EJ: Velocardiofacial (Shprintzen) syndrome: An important syndrome for the dysmorphologist to recognise. J Med Genet 28:596, 1991[Abstract/Free Full Text]

202. Ware J, Hashimoto Y, Zieger B, Russell S: Controlling elements of platelet glycoprotein Ibalpha expression. C R Acad Sci III 319:811, 1996[Medline] [Order article via Infotrieve]

203. Rendu F, Nurden AT, Lebert M, Caen JP: Relationship between mepacrine-labelled dense body number, platelet capacity to accumulate 14C-5-HT and platelet density in the Bernard-Soulier and Hermansky-Pudlak syndromes. Thromb Haemost 42:694, 1979[Medline] [Order article via Infotrieve]

204. McGregor JL, Clemetson KJ, James E, Luscher EF, Dechavanne M: A comparison of the major platelet membrane glycoproteins from Bernard-Soulier syndrome with normals after radiolabelling of sialic acid or terminal galactose/N-acetylgalactosamine residues. Thromb Res 17:713, 1980[Medline] [Order article via Infotrieve]

205. George JN, Reimann TA, Moake JL, Morgan RK, Cimo PL, Sears DA: Bernard-Soulier disease: A study of four patients and their parents. Br J Haematol 48:459, 1981[Medline] [Order article via Infotrieve]

206. Drouin J, McGregor JL, Parmentier S, Izaguirre CA, Clemetson KJ: Residual amounts of glycoprotein Ib concomitant with near-absence of glycoprotein IX in platelets of Bernard-Soulier patients. Blood 72:1086, 1988[Abstract/Free Full Text]

207. McGill M, Jamieson GA, Drouin J, Cho MS, Rock GA: Morphometric analysis of platelets in Bernard-Soulier syndrome: Size and configuration in patients and carriers. Thromb Haemost 52:37, 1984[Medline] [Order article via Infotrieve]

208. De Marco L, Fabris F, Casonato A, Fabris P, Dal Ben MG, Barbato A, Girolami A: Bernard-Soulier syndrome: diagnosis by an ELISA method using monoclonal antibodies in 2 new unrelated patients. Acta Haematol 75:203, 1986[Medline] [Order article via Infotrieve]

209. Ingerslev J, Stenbjerg S, Taaning E: A case of Bernard-Soulier syndrome: Study of platelet glycoprotein Ib in a kindred. Eur J Haematol 39:182, 1987[Medline] [Order article via Infotrieve]

210. Nicholas WL, Kaese SE, Gastineau DA, Otteman LA, Bowie EJW: Bernard-soulier syndrome: Whole blood diagnostic assays of platelets. Mayo Clinic Proc 64:522, 1989[Medline] [Order article via Infotrieve]

211. Finch CN, Miller JL, Lyle VA, Handin RI: Evidence that an abnormality in the glycoprotein Ib alpha gene is not the cause of abnormal platelet function in a family with classic Bernard-Soulier disease. Blood 75:2357, 1990[Abstract/Free Full Text]

212. Hourdillé P, Pico M, Jandrot-Perrus M, Lacaze D, Lozano M, Nurden AT: Studies on the megakaryocytes of a patient with the Bernard-Soulier syndrome. Br J Haematol 76:521, 1990[Medline] [Order article via Infotrieve]

213. Poulsen LO, Taaning E: Variation in surface platelet glycoprotein Ib expression in Bernard-Soulier syndrome. Haemostasis 20:155, 1990[Medline] [Order article via Infotrieve]

214. Clemetson JM, Kyrle PA, Brenner B, Clemetson KJ: Variant Bernard-Soulier syndrome associated with a homozygous mutation in the leucine-rich domain of glycoprotein IX. Blood 84:1124, 1994[Abstract/Free Full Text]

215. Arai M, Yamamoto N, Akamatsu N, Suzuki H, Yamaguchi A, Nishida Y, Fukutake K, Tanoue K: Substantial expression of glycoproteins IX and V on the platelet surface from a patient with Bernard-Soulier syndrome. Br J Haematol 87:185, 1994[Medline] [Order article via Infotrieve]

216. de La Salle C, Baas M-J, Lanza F, Schwartz A, Hanau D, Chevalier J, Gachet C, Briquel M, Cazenave J-P: A three-base deletion removing a leucine residue in a leucine-rich repeat of platelet glycoprotein Ibalpha associated with a variant of Bernard-Soulier syndrome (Nancy I). Br J Haematol 89:386, 1995[Medline] [Order article via Infotrieve]

217. Bellucci S, Zini JM, Bitoun P, Dupuy Y, Drouet L, Tobelem G, Caen JP: Diffuse severe digestive angiodysplasia in Bernard-Soulier syndrome. Improvement of bleeding by oestroprogestative therapy. Thromb Haemost 74:1610, 1995[Medline] [Order article via Infotrieve]

218. Kanaji T, Okamura T, Kuroiwa M, Noda M, Fujimura K, Kuramoto A, Sano M, Nakano S, Niho Y: Molecular and genetic analysis of two patients with Bernard-Soulier syndrome: Identification of new mutations in glycoprotein Ibalpha gene. Thromb Haemost 77:1055, 1997[Medline] [Order article via Infotrieve]

219. Noris P, Simsek S, Stibbe J, von dem Borne AEGK: A phenylalanine-55 to serine amino-acid substitution in the human glycoprotein IX leucine-rich repeat is associated with Bernard-Soulier syndrome. Br J Haematol 97:312, 1997[Medline] [Order article via Infotrieve]

© 1998 by The American Society of Hematology.
 
0006-4971/98/91-0042$3.00/0

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
A. Brill, A. K. Chauhan, M. Canault, M. T. Walsh, W. Bergmeier, and D. D. Wagner
Oxidative stress activates ADAM17/TACE and induces its target receptor shedding in platelets in a p38-dependent fashion
Cardiovasc Res, October 1, 2009; 84(1): 137 - 144.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
C. Strassel, A. Eckly, C. Leon, C. Petitjean, M. Freund, J.-P. Cazenave, C. Gachet, and F. Lanza
Intrinsic impaired proplatelet formation and microtubule coil assembly of megakaryocytes in a mouse model of Bernard-Soulier syndrome
Haematologica, June 1, 2009; 94(6): 800 - 810.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
J. Rivera, M. L. Lozano, L. Navarro-Nunez, and V. Vicente
Platelet receptors and signaling in the dynamics of thrombus formation
Haematologica, May 1, 2009; 94(5): 700 - 711.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
S. Vettore, R. Scandellari, S. Moro, A. M. Lombardi, M. Scapin, M. L. Randi, and F. Fabris
Novel point mutation in a leucine-rich repeat of the GPIb{alpha} chain of the platelet von Willebrand factor receptor, GPIb/IX/V, resulting in an inherited dominant form of Bernard-Soulier syndrome affecting two unrelated families: the N41H variant
Haematologica, November 1, 2008; 93(11): 1743 - 1747.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Ghevaert, A. Salsmann, N. A. Watkins, E. Schaffner-Reckinger, A. Rankin, S. F. Garner, J. Stephens, G. A. Smith, N. Debili, W. Vainchenker, et al.
A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the {alpha}IIb{beta}3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia
Blood, April 1, 2008; 111(7): 3407 - 3414.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
D. Varga-Szabo, I. Pleines, and B. Nieswandt
Cell Adhesion Mechanisms in Platelets
Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): 403 - 412.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Jain, M. Zuka, J. Liu, S. Russell, J. Dent, J. A. Guerrero, J. Forsyth, B. Maruszak, T. K. Gartner, B. Felding-Habermann, et al.
Platelet glycoprotein Ib{alpha} supports experimental lung metastasis
PNAS, May 22, 2007; 104(21): 9024 - 9028.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
C. V. Denis and D. D. Wagner
Platelet Adhesion Receptors and Their Ligands in Mouse Models of Thrombosis
Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 728 - 739.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
C. Strassel, C. Nonne, A. Eckly, T. David, C. Leon, M. Freund, J.-P. Cazenave, C. Gachet, and F. Lanza
Decreased Thrombotic Tendency in Mouse Models of the Bernard-Soulier Syndrome
Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 241 - 247.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
W. S. Alexander, E. M. Viney, J.-G. Zhang, D. Metcalf, M. Kauppi, C. D. Hyland, M. R. Carpinelli, W. Stevenson, B. A. Croker, A. A. Hilton, et al.
Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene
PNAS, October 31, 2006; 103(44): 16442 - 16447.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Mo, N. Lu, A. Padilla, J. A. Lopez, and R. Li
The Transmembrane Domain of Glycoprotein Ibbeta Is Critical to Efficient Expression of Glycoprotein Ib-IX Complex in the Plasma Membrane
J. Biol. Chem., August 11, 2006; 281(32): 23050 - 23059.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. J. Reininger, H. F. G. Heijnen, H. Schumann, H. M. Specht, W. Schramm, and Z. M. Ruggeri
Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress
Blood, May 1, 2006; 107(9): 3537 - 3545.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Nakamura, R. Pudas, O. Heikkinen, P. Permi, I. Kilpelainen, A. D. Munday, J. H. Hartwig, T. P. Stossel, and J. Ylanne
The structure of the GPIb-filamin A complex
Blood, March 1, 2006; 107(5): 1925 - 1932.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Aktas, M. Pozgajova, W. Bergmeier, S. Sunnarborg, S. Offermanns, D. Lee, D. D. Wagner, and B. Nieswandt
Aspirin Induces Platelet Receptor Shedding via ADAM17 (TACE)
J. Biol. Chem., December 2, 2005; 280(48): 39716 - 39722.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. L. Yee, C. W. Sun, A. L. Bergeron, J.-f. Dong, and P. F. Bray
Aggregometry detects platelet hyperreactivity in healthy individuals
Blood, October 15, 2005; 106(8): 2723 - 2729.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Othman, C. Notley, F. L. Lavender, H. White, C. D. Byrne, D. Lillicrap, and D. F. O'Shaughnessy
Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease
Blood, June 1, 2005; 105(11): 4330 - 4336.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Feng, X. Lu, and M. H. Kroll
Filamin A Binding Stabilizes Nascent Glycoprotein Ib{alpha} Trafficking and Thereby Enhances Its Surface Expression
J. Biol. Chem., February 25, 2005; 280(8): 6709 - 6715.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
R. I. Handin
Inherited Platelet Disorders
Hematology, January 1, 2005; 2005(1): 396 - 402.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Peng, M. C. Berndt, M. A. Cruz, and J. A. Lopez
The {alpha}1 helix-{beta}13 strand spanning Leu214 to Val229 of platelet glycoprotein Ib{alpha} facilitates the interaction with von Willebrand factor: evidence from characterization of the epitope of monoclonal antibody AP1
Blood, December 15, 2004; 104(13): 3971 - 3978.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Kanaji, S. Russell, J. Cunningham, K. Izuhara, J. E. B. Fox, and J. Ware
Megakaryocyte proliferation and ploidy regulated by the cytoplasmic tail of glycoprotein Ib{alpha}
Blood, November 15, 2004; 104(10): 3161 - 3168.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Kato, C. Martinez, S. Russell, P. Nurden, A. Nurden, S. Fiering, and J. Ware
Genetic deletion of mouse platelet glycoprotein Ib{beta} produces a Bernard-Soulier phenotype with increased {alpha}-granule size
Blood, October 15, 2004; 104(8): 2339 - 2344.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. L. Balduini and J. G. Drachman
Role of splenectomy in inherited thrombocytopenias
Blood, August 15, 2004; 104(4): 1227 - 1227.
[Full Text] [PDF]

Home page
 BloodHome page
P. Mangin, T. David, V. Lavaud, S. L. Cranmer, I. Pikovski, S. P. Jackson, M. C. Berndt, J.-P. Cazenave, C. Gachet, and F. Lanza
Identification of a novel 14-3-3{zeta} binding site within the cytoplasmic tail of platelet glycoprotein Ib{alpha}
Blood, July 15, 2004; 104(2): 420 - 427.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Shimizu, T. Matsushita, T. Kondo, Y. Inden, T. Kojima, H. Saito, and M. Hirai
Identification of the Amino Acid Residues of the Platelet Glycoprotein Ib (GPIb) Essential for the von Willebrand Factor Binding by Clustered Charged-to-Alanine Scanning Mutagenesis
J. Biol. Chem., April 16, 2004; 279(16): 16285 - 16294.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
D. D. Wagner and P. C. Burger
Platelets in Inflammation and Thrombosis
Arterioscler Thromb Vasc Biol, December 1, 2003; 23(12): 2131 - 2137.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. F. Brass
Thrombin and Platelet Activation
Chest, September 1, 2003; 124 (2009): 18S - 25S.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
F. Locatelli, G. Rossi, and C. Balduini
Hematopoietic Stem-Cell Transplantation for the Bernard-Soulier Syndrome
Ann Intern Med, January 7, 2003; 138(1): 79 - 79.
[Full Text] [PDF]

Home page
 BloodHome page
T. Kanaji, S. Russell, and J. Ware
Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome
Blood, August 28, 2002; 100(6): 2102 - 2107.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Arya, B. Anvari, G. M. Romo, M. A. Cruz, J.-F. Dong, L. V. McIntire, J. L. Moake, and J. A. Lopez
Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers
Blood, May 13, 2002; 99(11): 3971 - 3977.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Li, X. Xi, and X. Du
A Mitogen-activated Protein Kinase-dependent Signaling Pathway in the Activation of Platelet Integrin alpha IIbbeta 3
J. Biol. Chem., November 2, 2001; 276(45): 42226 - 42232.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
Zhaoyue Wang, Jumei Shi, Yue Han, Yingchun Wang, and Changgeng Ruan
Spontaneous Platelet Aggregation With Congenital Giant Platelet Containing Large Granules and Thick Membrane
Clinical and Applied Thrombosis/Hemostasis, October 1, 2001; 7(4): 305 - 310.
[Abstract] [PDF]

Home page
 BloodHome page
H. Ni, V. Ramakrishnan, Z. M. Ruggeri, J. M. Papalia, D. R. Phillips, and D. D. Wagner
Increased thrombogenesis and embolus formation in mice lacking glycoprotein V
Blood, July 15, 2001; 98(2): 368 - 373.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. I. Baker, J. Eikelboom, E. Lofthouse, N. Staples, V. Afshar-Kharghan, J. A. Lopez, Y. Shen, M. C. Berndt, and G. Hankey
Platelet glycoprotein Ib{alpha} Kozak polymorphism is associated with an increased risk of ischemic stroke
Blood, July 1, 2001; 98(1): 36 - 40.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Savoia, C. L. Balduini, M. Savino, P. Noris, M. Del Vecchio, S. Perrotta, S. Belletti, V. Poggi, and A. Iolascon
Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard-Soulier syndrome
Blood, March 1, 2001; 97(5): 1330 - 1335.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. Ramakrishnan, F. DeGuzman, M. Bao, S. W. Hall, L. L. Leung, and D. R. Phillips
A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V
PNAS, February 13, 2001; 98(4): 1823 - 1828.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Moran, P. A. Morateck, A. Deering, M. Ryan, R. R. Montgomery, D. J. Fitzgerald, and D. Kenny
Surface expression of glycoprotein Ibalpha is dependent on glycoprotein Ibbeta : evidence from a novel mutation causing Bernard-Soulier syndrome
Blood, July 15, 2000; 96(2): 532 - 539.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
U. J. H. Sachs, V. Kiefel, M. Bohringer, V. Afshar-Kharghan, H. Kroll, and S. Santoso
Single amino acid substitution in human platelet glycoprotein Ibbeta is responsible for the formation of the platelet-specific alloantigen Iya
Blood, March 1, 2000; 95(5): 1849 - 1855.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. K. Rao and J. Gabbeta
Congenital Disorders of Platelet Signal Transduction
Arterioscler Thromb Vasc Biol, February 1, 2000; 20(2): 285 - 289.
[Full Text] [PDF]

Home page
 BloodHome page
Y. Shen, G. M. Romo, J.-f. Dong, A. Schade, L. V. McIntire, D. Kenny, J. C. Whisstock, M. C. Berndt, J. A. Lopez, and R. K. Andrews
Requirement of leucine-rich repeats of glycoprotein (GP) Ibalpha for shear-dependent and static binding of von Willebrand factor to the platelet membrane GP Ib-IX-V complex
Blood, February 1, 2000; 95(3): 903 - 910.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
M. Gu, X. Xi, G. D. Englund, M. C. Berndt, and X. Du
Analysis of the Roles of 14-3-3 in the Platelet Glycoprotein Ib-IX-Mediated Activation of Integrin {alpha}IIb{beta}3 Using a Reconstituted Mammalian Cell Expression Model
J. Cell Biol., November 29, 1999; 147(5): 1085 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. Ramakrishnan, P. S. Reeves, F. DeGuzman, U. Deshpande, K. Ministri-Madrid, R. B. DuBridge, and D. R. Phillips
Increased thrombin responsiveness in platelets from mice lacking glycoprotein V
PNAS, November 9, 1999; 96(23): 13336 - 13341.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
G. M. Romo, J.-F. Dong, A. J. Schade, E. E. Gardiner, G. S. Kansas, C. Q. Li, L. V. McIntire, M. C. Berndt, and J. A. Lopez
The Glycoprotein Ib-IX-V Complex Is a Platelet Counterreceptor for P-Selectin
J. Exp. Med., September 20, 1999; 190(6): 803 - 814.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Feng, N. Christodoulides, and M. H. Kroll
The Glycoprotein Ib/IX Complex Regulates Cell Proliferation
Blood, June 15, 1999; 93(12): 4256 - 4263.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Tan, M. A. Kowalska, G. M. Romo, J. A. Lopez, Z. Darzynkiewicz, and S. Niewiarowski
Identification and Characterization of Endothelial Glycoprotein Ib Using Viper Venom Proteins Modulating Cell Adhesion
Blood, April 15, 1999; 93(8): 2605 - 2616.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. D. Englund, R. J. Bodnar, Z. Li, Z. M. Ruggeri, and X. Du
Regulation of von Willebrand Factor Binding to the Platelet Glycoprotein Ib-IX by a Membrane Skeleton-dependent Inside-out Signal
J. Biol. Chem., May 11, 2001; 276(20): 16952 - 16959.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Williamson, I. Pikovski, S. L. Cranmer, P. Mangin, N. Mistry, T. Domagala, S. Chehab, F. Lanza, H. H. Salem, and S. P. Jackson
Interaction between Platelet Glycoprotein Ibalpha and Filamin-1 Is Essential for Glycoprotein Ib/IX Receptor Anchorage at High Shear
J. Biol. Chem., January 11, 2002; 277(3): 2151 - 2159.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J.-f. Dong, A. J. Schade, G. M. Romo, R. K. Andrews, S. Gao, L. V. McIntire, and J. A. Lopez
Novel Gain-of-function Mutations of Platelet Glycoprotein Ibalpha by Valine Mutagenesis in the Cys209-Cys248 Disulfide Loop. FUNCTIONAL ANALYSIS UNDER STATIC AND DYNAMIC CONDITIONS
J. Biol. Chem., September 1, 2000; 275(36): 27663 - 27670.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Ware, S. Russell, and Z. M. Ruggeri
Generation and rescue of a murine model of platelet dysfunction: The Bernard-Soulier syndrome
PNAS, March 14, 2000; 97(6): 2803 - 2808.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by López, J. A.
Right arrow Articles by Berndt, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by López, J. A.
Right arrow Articles by Berndt, M. C.
Related Collections
Right arrow Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1998 by American Society of Hematology         Online ISSN: 1528-0020